Patent Grant
12318636
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present disclosure details novel high intensity therapeutic ultrasound (HITU) systems configured to produce acoustic cavitation, methods, devices and procedures for the minimally and non-invasive treatment of healthy, diseased and/or injured tissue. The acoustic cavitation systems and methods described herein, also referred to Histotripsy, may include transducers, drive electronics, positioning robotics, imaging systems, and integrated treatment planning and control software to provide comprehensive treatment and therapy for soft tissues in a patient.
Histotripsy, or pulsed ultrasound cavitation therapy, is a technology where extremely short, intense bursts of acoustic energy induce controlled cavitation (microbubble formation) within the focal volume. The vigorous expansion and collapse of these microbubbles mechanically homogenizes cells and tissue structures within the focal volume. This is a very different end result than the coagulative necrosis characteristic of thermal ablation. To operate within a non-thermal, Histotripsy realm; it is necessary to deliver acoustic energy in the form of high amplitude acoustic pulses with low duty cycle.
Compared with conventional focused ultrasound technologies, Histotripsy has important advantages: 1) the destructive process at the focus is mechanical, not thermal; 2) cavitation appears bright on ultrasound imaging thereby confirming correct targeting and localization of treatment; 3) treated tissue generally, but not always, appears darker (more hypoechoic) on ultrasound imaging, so that the operator knows what has been treated; and 4) Histotripsy produces lesions in a controlled and precise manner. It is important to emphasize that unlike thermal ablative technologies such as microwave, radiofrequency, high-intensity focused ultrasound (HIFU) cryo or radiation, Histotripsy relies on the mechanical action of cavitation for tissue destruction and not on heat, cold or ionizing energy.
The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
A method of delivering histotripsy therapy to a target tissue is provided, comprising: receiving a digital treatment plan that includes a target tissue volume of a subject divided into a plurality of discrete treatment locations; mechanically positioning a focus of an ultrasound therapy transducer at a first focal location in a first discrete treatment location within the target tissue volume; delivering a first histotripsy pulse to the first focal location to produce a first cavitation bubble cloud at the first focal location; electronically beam-steering the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that overlaps with the first focal location; and delivering a second histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location and to at least partially re-excite the first cavitation bubble cloud at the first focal location.
In some aspects, the histotripsy pulse comprises a positive half-cycle followed by a peak negative half-cycle followed by a trailing positive half-cycle.
In some aspects, the trailing positive half-cycle has an amplitude lower than that of the leading positive half-cycle
In one aspect, delivering the second histotripsy pulse to the second focal location further comprises delivering the second histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of the first bubble cloud.
In other aspects, delivering the second histotripsy pulse to the second focal location further comprises delivering the second histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of residual cavitation nuclei of the first bubble cloud.
In one aspect, electronically beam-steering the focus further comprises electronically beam-steering the focus in an axial direction with respect to the ultrasound therapy transducer.
In other aspects, electronically beam-steering the focus further comprises electronically beam-steering the focus in any lateral direction with respect to the ultrasound therapy transducer.
In some aspects, electronically beam-steering the focus further comprises electronically beam-steering the focus in a lateral and an axial direction with respect to the ultrasound therapy transducer.
In another aspect, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the second focal location.
In some aspects, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the first focal location.
In one aspect, after each delivering step, the method includes delivering at least one low amplitude waveform into the target tissue to spatially manipulate residual cavitation nuclei in the target tissue.
In other aspects, the method includes repeating the delivering and electronically beam-steering steps for the first and second focal locations until a desired dose is applied to the first discrete treatment location.
In some aspects the method includes mechanically positioning the focus of the ultrasound therapy transducer at a first focal location in a second discrete treatment location within the target tissue volume after the desired dose has been applied to the first discrete treatment location.
In one aspect, the method includes mechanically positioning the focus further comprises mechanically positioning the focus with a robotic positioning system.
An ultrasound therapy system is provided, comprising; optionally a robotic positioning system; an ultrasound therapy transducer array connected to the robotic positioning system; a generator operatively coupled to the ultrasound therapy transducer array, the generator and ultrasound therapy transducer array being configured to deliver histotripsy pulses into a subject to generate a cavitation bubble cloud in the subject; at least one processor operatively coupled to the robotic positioning system and the generator, the at least one processor being configured to control the robotic positioning system and the generator to provide histotripsy therapy to the subject according to a treatment plan that includes a plurality of discrete treatment locations within a target tissue volume of the subject by: controlling the robotic positioning system to mechanically position a focus of the ultrasound therapy transducer array at a first focal location in a first discrete treatment location within the treatment plan; controlling the generator to deliver at least one histotripsy pulse with the ultrasound therapy transducer array to form a first cavitation bubble cloud at the first focal location; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that overlaps with the first focal location; and controlling the generator to deliver at least one histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location and to re-excite the first cavitation bubble cloud at the first focal location.
In some aspects, each of the histotripsy pulses comprises a positive half-cycle followed by a peak negative half-cycle followed by a trailing positive half-cycle.
In one aspect, the trailing positive half-cycle has an amplitude lower than that of the leading positive half-cycle.
In one aspect, controlling the generator to deliver the at least one histotripsy pulse to the second focal location further comprises controlling the generator to deliver the at least one histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of the first bubble cloud.
In other aspects, controlling the generator to deliver the at least one histotripsy pulse to the second focal location further comprises controlling the generator to deliver the at least one histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of residual cavitation nuclei of the first bubble cloud.
In some aspects, controlling the generator to electronically beam-steer the focus further comprises controlling the generator to electronically beam-steer the focus in an axial direction with respect to the ultrasound therapy transducer array.
In some aspects, controlling the generator to electronically beam-steer the focus further comprises controlling the generator to electronically beam-steer the focus in any lateral direction with respect to the ultrasound therapy transducer array.
In some aspects, controlling the generator to electronically beam-steer the focus further comprises controlling the generator to electronically beam-steer the focus in a lateral and an axial direction with respect to the ultrasound therapy transducer array.
In one aspect, the system is configured to repeat controlling the generator to electronically beam-steer and controlling the generator to deliver at least one histotripsy pulse for a third focal location that overlaps with the second focal location.
In other aspects, the system is configured to repeat controlling the generator to electronically beam-steer and controlling the generator to deliver at least one histotripsy pulse for a third focal location that overlaps with the first focal location.
In one aspect, after controlling the generator to deliver at least one histotripsy pulse the system is configured to control the generator to deliver at least one low amplitude waveform into the target tissue to spatially manipulate residual cavitation nuclei in the target tissue.
In one aspect, the system is configured for repeating controlling the generator to electronically beam-steer and controlling the generator to deliver at least one histotripsy pulse for the first and second focal locations until a desired dose is applied to the first discrete treatment location.
In other aspects, the system is configured for controlling the robotic positioning system to mechanically position the focus of the ultrasound therapy transducer at a first focal location in a second discrete treatment location within the target tissue volume after the desired do se has been applied to the first discrete treatment location.
A method of delivering histotripsy therapy to a target tissue volume is provided, comprising the steps of: dividing the target tissue volume into a plurality of discrete treatment locations; determining a treatment plan that includes a pathway for providing therapy to each of the discrete treatment locations; positioning a focus of an ultrasound therapy transducer at a first focal location in a first discrete treatment location within the target tissue volume; delivering one or more histotripsy pulses to the first focal location to produce a first bubble cloud at the first focal location; electronically beam-steering the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that overlaps with the first focal location; delivering one or more histotripsy pulses to the second focal location to produce a second bubble cloud at the second focal location; and repeating the positioning and delivering steps for each of the plurality of discrete treatment locations according to the treatment plan and pathway.
In one aspect, each histotripsy pulse comprises a positive half-cycle followed by a peak negative half-cycle followed by a trailing positive half-cycle.
In other aspects, the trailing positive half-cycle has an amplitude lower than that of the leading positive half-cycle.
In some aspects, the method includes delivering the one or more histotripsy pulses to the second focal location further comprises delivering the one or more histotripsy pulses to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of the first bubble cloud.
In other aspects, the method includes delivering the one or more histotripsy pulses to the second focal location further comprises delivering the one or more histotripsy pulses to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of residual cavitation nuclei of the first bubble cloud.
In some aspects, electronically beam-steering the focus further comprises electronically beam-steering the focus in an axial direction with respect to the ultrasound therapy transducer.
In other aspects, electronically beam-steering the focus further comprises electronically beam-steering the focus in any lateral direction with respect to the ultrasound therapy transducer.
In one aspect, electronically beam-steering the focus further comprises electronically beam-steering the focus in a lateral and an axial direction with respect to the ultrasound therapy transducer.
In another aspect, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the second focal location.
In some aspects, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the first focal location.
In another aspect, after each delivering step the method includes delivering at least one low amplitude waveform into the target tissue to spatially manipulate residual cavitation nuclei in the target tissue.
In some aspects, the method includes repeating the delivering and electronically beam-steering steps for the first and second focal locations until a desired dose is applied to the first discrete treatment location.
In another aspect, the method includes mechanically positioning the focus of the ultrasound therapy transducer at a first focal location in a second discrete treatment location within the target tissue volume after the desired dose has been applied to the first discrete treatment location.
In some aspects, mechanically positioning the focus further comprises mechanically positioning the focus with a robotic positioning system.
A method of delivering histotripsy therapy to a target tissue volume is provided, comprising: delivering first histotripsy therapy pulses to a first focal location to create a corresponding bubble cloud within a first focal zone; electronically beam-steering the focus a second focal location; and delivering second histotripsy therapy pulses to the second focal location to create a corresponding bubble cloud within a second focal zone that spatially overlaps with the first focal zone; wherein the second histotripsy pulses are timed to re-excite residual cavitation nuclei in the first focal zone to create an enhanced excitation volume comprising the first focal zone and second focal zone.
In some aspects, the histotripsy pulse comprises a positive half-cycle followed by a peak negative half-cycle followed by a trailing positive half-cycle.
In other aspects, the trailing positive half-cycle has an amplitude lower than that of the leading positive half-cycle.
In some aspects, delivering the second histotripsy pulse to the second focal location further comprises delivering the second histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of the first bubble cloud.
In another aspect, delivering the second histotripsy pulse to the second focal location further comprises delivering the second histotripsy pulse to the second focal location to produce the second bubble cloud at the second focal location during a life-cycle of residual cavitation nuclei of the first bubble cloud.
In some aspects, electronically beam-steering the focus further comprises electronically beam-steering the focus in an axial direction with respect to the ultrasound therapy transducer.
In one aspect, electronically beam-steering the focus further comprises electronically beam-steering the focus in any lateral direction with respect to the ultrasound therapy transducer.
In another aspect, electronically beam-steering the focus further comprises electronically beam-steering the focus in a lateral and an axial direction with respect to the ultrasound therapy transducer.
In some aspects, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the second focal location.
In other aspects, the method includes repeating the electronic beam-steering and delivering steps for a third focal location that overlaps with the first focal location.
In one aspect, after each delivering step, the method includes delivering at least one low amplitude waveform into the target tissue to spatially manipulate residual cavitation nuclei in the target tissue.
In some aspects, the method includes repeating the delivering and electronically beam-steering steps for the first and second focal locations until a desired dose is applied to the first discrete treatment location.
In other aspects, the method includes mechanically positioning the focus of the ultrasound therapy transducer at a first focal location in a second discrete treatment location within the target tissue volume after the desired dose has been applied to the first discrete treatment location.
In some aspects, mechanically positioning the focus further comprises mechanically positioning the focus with a robotic positioning system.
A method of producing an enhanced excitation volume with histotripsy energy is provided, comprising positioning a focus of an ultrasound therapy transducer at a first focal location in a first discrete treatment location within a target tissue volume, the first focal location being positioned along a central axis of the ultrasound therapy transducer, delivering a first histotripsy pulse to the first focal location to produce a first cavitation bubble cloud at the first focal location, electronically beam-steering the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that is at least partially outside of the central axis, delivering a second histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location, electronically beam-steering the focus of the ultrasound therapy transducer to a focal location at least partially inside the central axis; and delivering a third histotripsy pulse to the focal location to produce a third bubble cloud at the focal location.
In some aspects, a natural focus of the ultrasound therapy transducer array is located along the central axis.
In other aspects, the first focal location comprises the natural focus.
In some aspects, the second focal location partially overlaps with the central axis.
In other aspects, the focal location comprises the first focal location.
In additional aspects, the focal location comprises a third focal location.
In some aspects, electronically beam-steering to the second focal location comprises steering laterally.
In other aspects, electronically beam-steering to the second focal location comprises steering laterally and axially.
An ultrasound therapy system is provided, comprising; a robotic positioning system; an ultrasound therapy transducer array connected to the robotic positioning system; a generator operatively coupled to the ultrasound therapy transducer array, the generator and ultrasound therapy transducer array being configured to deliver histotripsy pulses into a subject to generate a cavitation bubble cloud in the subject; at least one processor operatively coupled to the robotic positioning system and the generator, the at least one processor being configured to control the robotic positioning system and the generator to provide histotripsy therapy to the subject according to a treatment plan that includes a plurality of discrete treatment locations within a target tissue volume of the subject by: controlling the robotic positioning system to mechanically position a focus of the ultrasound therapy transducer array at a first focal location in a first discrete treatment location within the treatment plan, the first focal location being positioned along a central axis of the ultrasound therapy transducer array; controlling the generator to deliver at least one histotripsy pulse with the ultrasound therapy transducer array to form a first cavitation bubble cloud at the first focal location; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that is at least partially outside the central axis; controlling the generator to deliver at least one histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a focal location in the first discrete treatment location that is at least partially inside the central axis; and controlling the generator to deliver at least one histotripsy pulse to the focal location to produce a third bubble cloud at the focal location.
In some aspects, a natural focus of the ultrasound therapy transducer array is located along the central axis.
In other aspects, the first focal location comprises the natural focus.
In some aspects, the second focal location partially overlaps with the central axis.
In other aspects, the focal location comprises the first focal location.
In some aspects, the focal location comprises a third focal location.
In other aspects, the system is configured for controlling the generator to electronically beam-steer to the second focal location comprises steering laterally.
In other aspects, the system is configured for controlling the generator to electronically beam-steer to the second focal location comprises steering laterally and axially.
An ultrasound therapy system is provided, comprising; an ultrasound therapy transducer array; a generator operatively coupled to the ultrasound therapy transducer array, the generator and ultrasound therapy transducer array being configured to deliver histotripsy pulses into a subject to generate a cavitation bubble cloud in the subject; at least one processor operatively coupled to the generator, the at least one processor being configured to control the generator to provide histotripsy therapy to the subject according to a treatment plan that includes a plurality of discrete treatment locations within a target tissue volume of the subject by: controlling the generator to deliver at least one histotripsy pulse with the ultrasound therapy transducer array to form a first cavitation bubble cloud at a first focal location in a first discrete treatment location within the treatment plan; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that overlaps with the first focal location; and controlling the generator to deliver at least one histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location and to re-excite the first cavitation bubble cloud at the first focal location.
An ultrasound therapy system is provided, comprising; an ultrasound therapy transducer array; a generator operatively coupled to the ultrasound therapy transducer array, the generator and ultrasound therapy transducer array being configured to deliver histotripsy pulses into a subject to generate a cavitation bubble cloud in the subject; at least one processor operatively coupled to the generator, the at least one processor being configured to control the generator to provide histotripsy therapy to the subject according to a treatment plan that includes a plurality of discrete treatment locations within a target tissue volume of the subject by: controlling the generator to deliver at least one histotripsy pulse with the ultrasound therapy transducer array to form a first cavitation bubble cloud at a first focal location in a first discrete treatment location within the treatment plan, the first focal location being positioned along a central axis of the ultrasound therapy transducer array; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a second focal location in the first discrete treatment location that is at least partially outside the central axis; controlling the generator to deliver at least one histotripsy pulse to the second focal location to produce a second bubble cloud at the second focal location; controlling the generator to electronically beam-steer the focus of the ultrasound therapy transducer to a focal location in the first discrete treatment location that is at least partially inside the central axis; and controlling the generator to deliver at least one histotripsy pulse to the focal location to produce a third bubble cloud at the focal location.
The system, methods and devices of the disclosure may be used for open surgical, minimally invasive surgical (laparoscopic and percutaneous), robotic surgical (integrated into a robotically-enabled medical system), endoscopic or completely transdermal extracorporeal non-invasive acoustic cavitation for the treatment of healthy, diseased and/or injured tissue including but not limited to tissue destruction, cutting, skeletonizing and ablation. Furthermore, due to tissue selective properties, histotripsy may be used to create a cytoskeleton that allows for subsequent tissue regeneration either de novo or through the application of stem cells and other adjuvants. Finally, histotripsy can be used to cause the release of delivered agents such as chemotherapy and immunotherapy by locally causing the release of these agents by the application of acoustic energy to the targets. As will be described below, the acoustic cavitation system may include various sub-systems, including a Cart, Therapy, Integrated Imaging, Robotics, Coupling and Software. The system also may comprise various Other Components, Ancillaries and Accessories, including but not limited to computers, cables and connectors, networking devices, power supplies, displays, drawers/storage, doors, wheels, and various simulation and training tools, etc. All systems, methods and means creating/controlling/delivering histotripsy are considered to be a part of this disclosure, including new related inventions disclosed herein.
The histotripsy system may comprise one or more of various sub-systems, including a Therapy sub-system that can create, apply, focus and deliver acoustic cavitation/histotripsy through one or more therapy transducers, Integrated Imaging sub-system (or connectivity to) allowing real-time visualization of the treatment site and histotripsy effect through-out the procedure, a Robotics positioning sub-system to mechanically and/or electronically steer the therapy transducer, further enabled to connect/support or interact with a Coupling sub-system to allow acoustic coupling between the therapy transducer and the patient, and Software to communicate, control and interface with the system and computer-based control systems (and other external systems) and various Other Components, Ancillaries and Accessories, including one or more user interfaces and displays, and related guided work-flows, all working in part or together. The system may further comprise various fluidics and fluid management components, including but not limited to, pumps, valve and flow controls, temperature and degassing controls, and irrigation and aspiration capabilities, as well as providing and storing fluids. It may also contain various power supplies and protectors.
As described above, the histotripsy system may include integrated imaging. However, in other embodiments, the histotripsy system can be configured to interface with separate imaging systems, such as C-arm, fluoroscope, cone beam CT, MRI, etc., to provide real-time imaging during histotripsy therapy. In some embodiments, the histotripsy system can be sized and configured to fit within a C-arm, fluoroscope, cone beam CT, MRI, etc.
Cart
The Cart 110 may be generally configured in a variety of ways and form factors based on the specific uses and procedures. In some cases, systems may comprise multiple Carts, configured with similar or different arrangements. In some embodiments, the cart may be configured and arranged to be used in a radiology environment and in some cases in concert with imaging (e.g., CT, cone beam CT and/or MRI scanning). In other embodiments, it may be arranged for use in an operating room and a sterile environment for open surgical or laparoscopic surgical and endoscopic application, or in a robotically enabled operating room, and used alone, or as part of a surgical robotics procedure wherein a surgical robot conducts specific tasks before, during or after use of the system and delivery of acoustic cavitation/histotripsy. As such and depending on the procedure environment based on the aforementioned embodiments, the cart may be positioned to provide sufficient work-space and access to various anatomical locations on the patient (e.g., torso, abdomen, flank, head and neck, etc.), as well as providing work-space for other systems (e.g., anesthesia cart, laparoscopic tower, surgical robot, endoscope tower, etc.).
The Cart may also work with a patient surface (e.g., table or bed) to allow the patient to be presented and repositioned in a plethora of positions, angles and orientations, including allowing changes to such to be made pre, peri and post-procedurally. It may further comprise the ability to interface and communicate with one or more external imaging or image data management and communication systems, not limited to ultrasound, CT, fluoroscopy, cone beam CT, PET, PET/CT, MRI, optical, ultrasound, and image fusion and or image flow, of one or more modalities, to support the procedures and/or environments of use, including physical/mechanical interoperability (e.g., compatible within cone beam CT work-space for collecting imaging data pre, peri and/or post histotripsy) and to provide access to and display of patient medical data including but not limited to laboratory and historical medical record data.
In some embodiments one or more Carts may be configured to work together. As an example, one Cart may comprise a bedside mobile Cart equipped with one or more Robotic arms enabled with a Therapy transducer, and Therapy generator/amplifier, etc., while a companion cart working in concert and at a distance of the patient may comprise Integrated Imaging and a console/display for controlling the Robotic and Therapy facets, analogous to a surgical robot and master/slave configurations.
In some embodiments, the system may comprise a plurality of Carts, all slave to one master Cart, equipped to conduct acoustic cavitation procedures. In some arrangements and cases, one Cart configuration may allow for storage of specific sub-systems at a distance reducing operating room clutter, while another in concert Cart may comprise essentially bedside sub-systems and componentry (e.g., delivery system and therapy).
One can envision a plethora of permutations and configurations of Cart design, and these examples are in no way limiting the scope of the disclosure.
Histotripsy
Histotripsy comprises short, high amplitude, focused ultrasound pulses to generate a dense, energetic, “bubble cloud”, capable of the targeted fractionation and destruction of tissue. Histotripsy is capable of creating controlled tissue erosion when directed at a tissue interface, including tissue/fluid interfaces, as well as well-demarcated tissue fractionation and destruction, at sub-cellular levels, when it is targeted at bulk tissue. Unlike other forms of ablation, including thermal and radiation-based modalities, histotripsy does not rely on heat cold or ionizing (high) energy to treat tissue. Instead, histotripsy uses acoustic cavitation generated at the focus to mechanically effect tissue structure, and in some cases liquefy, suspend, solubilize and/or destruct tissue into sub-cellular components.
Histotripsy can be applied in various forms, including: 1) Intrinsic-Threshold Histotripsy: Delivers pulses typically with a 1-2 cycles of high amplitude negative/tensile phase pressure exceeding the intrinsic threshold to generate cavitation in the medium (e.g., ˜24-28 MPa for water-based soft tissue), 2) Shock-Scattering Histotripsy: Delivers typically pulses 1-20 cycles in duration. The shockwave (positive/compressive phase) scattered from an initial individual microbubble generated forms inverted shockwave, which constructively interfere with the incoming negative/tensile phase to form high amplitude negative/rarefactional phase exceeding the intrinsic threshold. In this way, a cluster of cavitation microbubbles is generated. The amplitude of the tensile phases of the pulses is sufficient to cause bubble nuclei in the medium to undergo inertial cavitation within the focal zone throughout the duration of the pulse. These nuclei scatter the incident shockwaves, which invert and constructively interfere with the incident wave to exceed the threshold for intrinsic nucleation, and 3) Boiling Histotripsy: Employs pulses roughly 1-20 ms in duration. Absorption of the shocked pulse rapidly heats the medium, thereby reducing the threshold for intrinsic nuclei. Once this intrinsic threshold coincides with the peak negative pressure of the incident wave, boiling bubbles form at the focus.
The large pressure generated at the focus causes a cloud of acoustic cavitation bubbles to form above certain thresholds, which creates localized stress and strain in the tissue and mechanical breakdown without significant heat deposition. At pressure levels where cavitation is not generated, minimal effect is observed on the tissue at the focus. This cavitation effect is observed only at pressure levels significantly greater than those which define the inertial cavitation threshold in water for similar pulse durations, on the order of 10 to 30 MPa peak negative pressure.
Histotripsy may be performed in multiple ways and under different parameters. It may be performed entirely or completely non-invasively by acoustically coupling a focused ultrasound transducer over the skin of a patient and transmitting acoustic pulses transcutaneously through overlying (and intervening) tissue to the focal zone (treatment zone and site). The application of histotripsy is not limited to a transdermal approach but can be applied through any means that allows contact of the transducer with tissue including open surgical laparoscopic surgical, percutaneous and robotically mediated surgical procedures. It may be further targeted, planned, directed and observed under direct visualization, via ultrasound imaging, given the bubble clouds generated by histotripsy may be visible as highly dynamic, echogenic regions on, for example, B Mode ultrasound images, allowing continuous visualization through its use (and related procedures). Likewise, the treated and fractionated tissue shows a dynamic change in echogenicity (typically a reduction), which can be used to evaluate, plan, observe and monitor treatment.
Generally, in histotripsy treatments, ultrasound pulses with 1 or more acoustic cycles are applied, and the bubble cloud formation relies on the pressure release scattering of the positive shock fronts (sometimes exceeding 100 MPa, P+) from initially initiated, sparsely distributed bubbles (or a single bubble). This is referred to as the “shock scattering mechanism”.
When the amplitude(s) of positive half cycle(s) of each pulse are limited, shock scattering can be minimized, and the generation of a dense bubble cloud depends on the negative half cycle(s) of the applied ultrasound pulses exceeding an “intrinsic threshold” of the medium. This is referred to as the “intrinsic threshold mechanism”.
This threshold can be in the range of 26-30 MPa for soft tissues with high water content, such as tissues in the human body. In some embodiments, using this intrinsic threshold mechanism, the spatial extent of the lesion may be well-defined and more predictable. With peak negative pressures (P−) not significantly higher than this threshold, sub-wavelength reproducible lesions as small as half of the −6 dB beam width of a transducer may be generated.
With high-frequency Histotripsy pulses, the size of the smallest reproducible lesion becomes smaller, which is beneficial in applications that require precise lesion generation. However, high-frequency pulses are more susceptible to attenuation and aberration, rendering problematical treatments at a larger penetration depth (e.g., ablation deep in the body) or through a highly aberrative medium (e.g., transcranial procedures, or procedures in which the pulses are transmitted through bone(s)). Histotripsy may further also be applied as a low-frequency “pump” pulse (typically <2 cycles and having a frequency between 100 kHz and 1 MHz) can be applied together with a high-frequency “probe” pulse (typically <2 cycles and having a frequency greater than 2 MHz, or ranging between 2 MHz and 10 MHz) wherein the peak negative pressures of the low and high-frequency pulses constructively interfere to exceed the intrinsic threshold in the target tissue or medium. The low-frequency pulse, which is more resistant to attenuation and aberration, can raise the peak negative pressure P— level for a region of interest (ROI), while the high-frequency pulse, which provides more precision, can pin-point a targeted location within the ROI and raise the peak negative pressure P− above the intrinsic threshold. This approach may be referred to as “dual frequency”, “dual beam histotripsy” or “parametric histotripsy.”
Additional systems, methods and parameters to deliver optimized histotripsy, using shock scattering, intrinsic threshold, and various parameters enabling frequency compounding and bubble manipulation, are herein included as part of the system and methods disclosed herein, including additional means of controlling said histotripsy effect as pertains to steering and positioning the focus, and concurrently managing tissue effects (e.g., prefocal thermal collateral damage) at the treatment site or within intervening tissue. Further, it is disclosed that the various systems and methods, which may include a plurality of parameters, such as but not limited to, frequency, operating frequency, center frequency, pulse repetition frequency, pulses, bursts, number of pulses, cycles, length of pulses, amplitude of pulses, pulse period, delays, burst repetition frequency, sets of the former, loops of multiple sets, loops of multiple and/or different sets, sets of loops, and various combinations or permutations of, etc., are included as a part of this disclosure, including future envisioned embodiments of such.
Challenges of Residual/Remnant Cavitation Nuclei
The concept of residual/remnant cavitation nuclei is known. It relates to the phenomenon that after a bubble cloud is generated and rapidly collapses within a medium (e.g., tissue), bubbles may remain sparsely distributed throughout the medium where prior histotripsy therapy has been applied. In some situations, the residual cavitation nuclei can affect histotripsy treatment and can create undesirable local environments that can challenge the ability to deliver histotripsy, effectively. This includes their ability to seed cavitation by subsequent therapy pulses, influencing the spatial distribution of subsequent bubble clouds such that cavitation occurs at prior treated locations (i.e., cavitation memory effect), while other and/or adjacent sites may experience reduced bubble cloud exposure or undertreatment. In some scenarios and conditions, remnant nuclei may result in bubble clouds forming preferentially where the remnant nuclei are located and at a distance from the prescribed focal location, resulting in less uniform treatment and/or distribution of treatment through the larger planned volume. Furthermore, and potentially more problematic in some cases, remnant nuclei can cause shielding/attenuation of subsequent pulses if they exist along the acoustic propagation path such that they can attenuate the incident therapy waveforms and reduce the energy delivered to tissue. In some examples, they may partially or fully block therapy.
Bubble Cloud Enhancement With Rapid Steering Between Overlapping Focal Zones
As described above, histotripsy therapy bubble clouds can be generated in a number of ways, including methods based on shock scattering and intrinsic threshold pulses. These sequences may include, but are not limited to, various types of pulses, including therapy, bubble manipulation pulses, etc. In some cases, bubble manipulation pulses may be used to modify the focal and treatment zone in effort to move or manipulate residual bubbles/nuclei remaining from prior pulses, which may adversely affect histotripsy treatments (e.g., act as blockers to subsequent histotripsy pulses).
This disclosure provides electronic beam-steering strategies configured to modify a single focal location environment to overcome the blockage, attenuation, and cavitation memory effect. This disclosure further provides additional systems, methods, and techniques to advantageously use adjacent residual cavitation nuclei to produce enhanced or enlarged cavitation bubble clouds in a highly controlled manner through the use of specifically designed computer-controlled hardware/software systems.
Provided herein are novel systems and methods for forming “enhanced excitation volumes” by enhancing, enlarging, and/or shaping a defined histotripsy “excitation volume”, leveraging unique approaches to re-excite remnant nuclei to create a larger bubble cloud than would be possible without remnant nuclei re-excitation. For purposes of this disclosure, an “excitation volume” can comprise a volume within which a cavitation bubble cloud generated by a single, discrete focal location with an ultrasound therapy transducer array is expected to be formed. An “enhanced excitation volume” can comprise an enhanced or enlarged volume within which a cavitation bubble cloud generated by overlapping focal locations with electronic beam-steering of the ultrasound therapy transducer array between the overlapping focal locations is expected to be formed. As described herein, the pulse sequences and electronic beam-steering for enhanced excitation volumes can be chosen to advantageously exploit residual cavitation nuclei to enhance the volume of cavitation formed in a highly controlled manner. The systems and methods that enable this enhanced excitation volume may generally include 1) initiation of a bubble cloud at a first focal location (e.g., a natural focus of the therapy transducer array) and creation of a corresponding volume referred to as the “focal zone”, 2) electronically beam-steering (e.g., phased array beam-steering) the focus to one or more additional focal locations in 2D (two-dimensional) or 3D (three-dimensional) space for creation of corresponding focal zones, 3) wherein the corresponding focal zone(s) are at least partially overlapping (with the first/prior focal zone volume(s)) and temporally and spatially positioned where pressures are within a threshold or range of the peak-pressure of the prior focal location/zone, 4) to re-excite remaining remnant nuclei (in the overlapping volume), 5) which together create the overall enhanced excitation volume or “larger bubble cloud” as shown in at least
The above-described enhanced excitation volumes may be created in unlimited permutations, based on the selection of, but not limited to, the spatial and temporal parameters for creating these 3D excitation volumes. They may be comprised of varied shape and size by in part modifying the position of the steered focal locations in 3D space (and corresponding focal zones), the specific range and spacing of overlap of focal zones, beam profile overlap, maximum distance from the first focal location to the most distant focal location, sequencing, timing and/or phasing of therapy and/or bubble manipulation pulses including any pauses or wait periods, and/or the number of pulses per focal location and total number of pulses applied to the defined 3D excitation volume to continuously grow and/or fill in the excitation volume.
Further, in some embodiments, the design of the steering direction may be selected to allow the rapid steering and re-excitement of remnant nuclei, but to also minimize the need to steer directly distal to a focal location that was targeted immediately prior to aid in minimizing shielding or blocking effects not conducive to re-exciting the desired effect for creating larger excitation volumes As will be described later, the order of the steered locations can be of importance in minimizing the shielding or blocking effects not conducive to the invention of the present disclosure.
Spatial and Temporal Considerations
The enhanced excitation volumes described above may be designed, configured, and optimized based on various spatial and temporal considerations of 1) the spacing of the selected focal locations/zones so that the focal zone of a subsequent pulse overlaps with the focal zone of the/a previous pulse and 2) the timing of the subsequent pulse within a time span sufficient to re-excite residual nuclei present in the overlapping zone from one or more previous pulses.
The selection of spacing parameters may include selecting both the distance between adjacent focal locations, as well as the distance (range) between the most extreme focal locations. In some embodiments, there may be a plurality of focal location positions at uniformly and/or non-uniformly spaced coordinates (x, y, z), which may be selected/defined based on desired target excitation volume size (e.g., specific spacing values may result in varied per pulse bubble cloud area). The selection of these parameters may also be based on the specific histotripsy sequence, acoustic field properties and corresponding bubble cloud size. In some examples, the distance between steered focal locations may be based on the wavelength of the therapy pulses. In particular, the beam profile can be proportional to the wavelength of the ultrasound signal. In some implementations, the longer the wavelength of the ultrasound signal, the larger the beam profile. Similarly, the shorter the wavelength of the ultrasound signal, the smaller the beam profile. Furthermore, the beam profile in each axis (x, y, z) is also affected by the specific geometry of the therapy transducer. For example, transducers with f-numbers between 0.5 and 1 may result in pulses that generate “elongate” bubble clouds that have longer z dimensions than dimensions in x or y. Following this same principle, this may allow for the ability to electronically steer to a greater distance in the z direction than in x and y.
In terms of additional temporal aspects, the timing of electronic steering to adjacent or distant focal locations (and creation of overlapping focal zones), may use similar or varied pulse repetition frequency (PRF) and steering periods, and may be selected based on desired dose delivered. In one example, an enhanced excitation volume is created using one representative histotripsy pulse delivered to a first focal location at a selected PRF, and a following pulse is electronically beam-steered and delivered to a subsequent (or second) focal location that overlaps with the first focal location, wherein the steering period (amount of time from one electronic steering event to the next) is equivalent to the therapy PRF (amount of time from one therapy pulse to the next). This may be repeated until the total desired number of therapy pulses are delivered to the enhanced excitation volume. In other examples, based on the number and position of steered focal locations, some steered locations may have the same or different pulse(s), steering period or PRF, and/or other therapy parameters. For example, the electronic steering period may be shorter (faster) than the PRF. The systems described herein may also have embedded logic and/or algorithms to account and/or adjust for the spatial/temporal relationships.
Volumes may be created based on the selection of spacing distances, various shapes, and morphologies of excitation volumes. These may include continuous or discontinuous volumes and the selection of these parameters may be based on application (e.g., complete tumor destruction versus gross tissue debulking, etc.). As a representative example, some excitation volumes may be ellipsoidal in shape, whereas others may be more bulb-like. Other shapes and geometries of excitation volumes are envisioned and within the scope of this disclosure.
In some embodiments, these may be created by using rapid axial beam-steering (z axis) over short distances between focal locations (<5 mm) of overlapping focal zones to aid in creating a longer continuous enhanced excitation volume but using approximately the same number of pulses for a single corresponding natural focus (only) bubble cloud. In some embodiments, lateral beam-steering (x-y axis) overlapping focal locations may be used. In other embodiments, a combination of axial and lateral electronic beam-steering between focal locations (and overlapping focal locations) may be used to create more spherical enhanced excitation volumes, in part to enable more efficient/easier packing of such volumes into a larger grid pattern of planned treatment volume. In some examples, the distribution of focal points within an electronic steering embodiment can be adjusted to alter an aspect ratio of the ellipsoidal cloud specific to best fit desired treatment patterns and plan geometries.
Planned Treatment Volumes Based on Patterned/Packed “Enhanced Excitation Volumes”
A plurality of enhanced excitation volumes (or larger bubble clouds) may also be arranged and packed into subsequent larger structures comprised of defined 3D patterns and shapes, of which may be used to create a defined planned treatment volume. For example, if the target tissue to be treated is a tumor, then the treatment volume can encompass the tumor (and any desired margins) and be filled with a plurality of enhanced excitation volumes. The plurality of enhanced excitation volumes may comprise one or more specific shapes or sizes (based on spatial selection of focal locations and how pulses are applied to those positions). The system and control software delivering therapy may also comprise logic to populate a desired and/or user selected planned treatment volume with enhanced excitation volumes using packing rules for the placement, position and numbers required to fill that desired volume/shape.
The further arrangement and packing of the enhanced excitation volumes may include the selection of their axial and radial spacing, and degree of overlap. Planned treatment volumes may comprise the packing of one iteration of an enhanced excitation volume or more than one variation of them. For example, larger enhanced excitation volumes may be packed more centrally within a planned treatment volume, with smaller excitation volumes positioned along the perimeter of the planned treatment volume. Rules and logic including overlapping of focal zones and temporal and distance spacing apply to both of the above examples and in other implementations discussed herein. In an analogous example, varied shapes may be used to pack planned treatment volumes as well. In this use case, the use of more eccentric ellipsoidal shapes may be positioned more centrally, with surrounding/adjacent enhanced treatment volumes being more spherical in shape to better enable packing the outer perimeter of a treatment volume (and plan).
In particular, the enhanced excitation volumes described are generally larger than an excitation volume formed by a single, discreet focal zone volume, such as an excitation volume formed at the natural focus of the therapy transducer array. Therefore, fewer enhanced excitation volumes are required to pack a given treatment volume, such as a 3 cm sphere, compared to the number of discreet excitation volumes that would be required to pack the same volume if the enhanced excitation volume techniques were not used. In some embodiments, for a given treatment plan, a specified number of pulses are calculated for each excitation volume or enhanced excitation volume comprising the treatment volume to achieve complete treatment of the treatment plan while managing the thermal dose delivered to the patient. The same number of pulses are employed for either discreet focal zones (excitation volumes) or enhanced excitation volumes. Because fewer enhanced excitation volumes are required to populate the planned treatment volume, faster treatment times are enabled with using enhanced excitation volumes.
In contrast,
In one specific implementation, an excitation volume formed at a natural focus of the ultrasound therapy transducer array, without rapid electronic beam-steering, can have volume dimensions of approximately 3 mm×3 mm×7 mm. In contrast, an enhanced excitation volume formed by rapid electronic beam-steering of the ultrasound transducer array can have volume dimensions of approximately 3 mm×3 mm×11 mm. With a treatment volume size of a 3 cm sphere in
Additionally, some permutations of parameters selected for the design of enhanced excitation volumes may preferentially assist in breaking through the physiomechanical interfaces of adjacent focal zones (e.g., between natural focus and subsequent beam-steered location(s)), and/or of adjacent excitation volumes (additional discrete positions of volumes placed adjacently as part of a larger 3D planned treatment volume).
During therapy, the histotripsy therapy transducer and robotic positioning system can then be configured to automatically traverse a focus of the therapy transducer sequentially through each of the discrete therapy locations of the planned treatment volume. This traversal can be, for example, mechanical movement of the histotripsy therapy transducer by physically changing a position/orientation of the histotripsy therapy transducer with the robotic positioning system.
Implementation of Enhanced Excitation Volumes
As described above, with a discrete excitation volume, the transducer focus is positioned at each discrete therapy location (e.g., planned focal locations) and a cavitation bubble cloud or focal zone is formed at each location for a pre-determined time based on the dose of therapy desired for each treatment location.
According to one aspect of this disclosure, as shown in
In the embodiment shown in
While the embodiment of
The distance of electronic beam-steering between focal locations/zones can vary, but in general the distance between the focal locations can be optimized based on the size of the bubble cloud generated by a chosen pulse. In some examples, the distance of steering between focal locations can be based on the wavelength of the ultrasound pulses and whether the steering is axial or lateral. For a histotripsy system using a selected pulse generating the bubble cloud sizes described and depicted in this disclosure, it has been found that optimal axial spacing between focal locations can be in the range of 1 mm to 5 mm between subsequent focal locations. In one embodiment, 2.5 mm spacing between focal locations advantageously provides sufficient overlap between bubble clouds at adjacent focal locations and optimally takes advantage over lower amplitude portions of the beam re-exciting residual cavitation nuclei in previously treated focal locations to improve the consistency and continuity of the bubble cloud across all the focal locations. In embodiments where the focal locations are laterally spaced from another, the range of movement/steering can differ from that of the axially spaced embodiment. Generally, lateral spacing can be within a 1 mm radius from the focus of the transducer. In one embodiment, 0.5 mm spacing between laterally spaced focal locations advantageously provides overlap between bubble clouds at adjacent focal locations and optimally takes advantage over lower amplitude portions of the beam re-exciting residual cavitation nuclei in previously treated focal locations to improve the consistency and continuity of the bubble cloud across all the focal locations.
The histotripsy pulse delivered to each focal location can comprise, for example, a shocked scattering histotripsy pulse, such as the one illustrated in
In one specific embodiment, the therapy pulses can have a repetition rate of ˜600 Hz, and timing of the rapid electronic beam-steering can be as follows: 1) One iteration of the therapy pulse is delivered to the first focal location (e.g., 504a in
Depending on the dose desired or prescribed for a given discrete treatment location, doses of therapy can be delivered multiple times to each focal location. For example, therapy can be provided to the first focal location, then the second focal location, then the third focal location, before moving back to the first focal location and repeating the process. In other embodiments, only a single dose at each focal location may be sufficient to achieve the desired dose for that treatment location. In some embodiments, the dose is varied spatially and temporally non-uniformly across a planned treatment volume comprised of a plurality of enhanced excitation volumes. For example, the extent of therapy in each iteration can also be configurable (e.g., n pulses delivered to a first focal location followed by n pulses delivered to a second focal location followed by n pulses delivered to a third focal location, where n could be equal to 1, 2, . . . , 100 or more, etc. prior to iterating through the focal locations again).
In the embodiment of
It should be understood that in other embodiments, the electronic beam-steering can be implemented laterally in the x-y direction. One example of lateral electronic beam-steering is shown in
While
While the beam-steering pattern of
Furthermore, according to some embodiments, the beam-steering pattern may revisit or repeat therapy delivery to some or all of the focal locations as the transducer array is beam-steered through the locations. The parameters for revisiting or repeating therapy delivery to focal locations can be predetermined, or customized by a user. In one embodiment, an important element of the electronically steered patterns is that in succession at the steered focal location within the enhanced volume there are both instances of new cavitation events and the restimulation of residual nuclei. In addition to these events at the current focal location, previously sonicated locations are being treated by the re-excitation of their residual nuclei. This process of periodically revisiting points can greatly assist in the sustained cavitation across the enhanced excitation volume, especially along a central axis of the transducer. In practice, it has been determined that periodically revisiting the central axis of the enhanced excitation volume during traversal of the electronic beam-steering pattern is beneficial to maintaining cavitation throughout the enhanced excitation volume.
Therefore, according to one embodiment and further depicted in
For example, one specific beam-steering pattern may require revisiting and re-exciting the natural focus (or a focal location central to the beam steering pattern) at least every 3 focal locations. Referring to
In some embodiments, the beam-steering pattern of
In one specific embodiment, the steering pattern is initiated by forming cavitation at the natural focus 804a of the central column 809a. Electronic beam-steering can then shift the focus of the transducer array to focal location 804b in column 809b (the central focal location in that column), then returning the focus to focal location 804c in column 809a. To complete excitation in both the central column and column 809b, the electronic beam-steering can continue by exciting focal location 804d in column 809b, then focal location 804e in central column 809a, then focal location 804f in column 809b. The steering pattern can then initiate cavitation in a new column (e.g., 809c), and continue the pattern of exciting a focal location in an outer or peripheral column followed by exciting a focal location in the central column. It is noted that in this specific implementation, the order of excitation/steering within the columns remains consistent. For example, the order of excitation of focal locations within the central column can start with the natural focus 804a, move to an outer or peripheral column, return to focal location 804c, move to the outer or peripheral portion, and then return to the central focal location 804e within the central column. Similarly, the pattern within outer or peripheral columns can also follow a specific sequence, e.g., starting with a central focal location within a given outer or peripheral column (e.g., focal location 804b in column 809b), returning to the central column, steering back to the lower or distal focal location in the outer or peripheral column (e.g., focal location 804d in column 809b), returning to the central column, and then moving to the top or proximal focal location in that column (e.g., focal location 804f in column 809b). In some embodiments, steering can be performed from the most distal point to the most proximal point in any series of three focal locations before returning to the most distal end of the pattern to begin a new series of three points.
In some aspects, the specific order of excitation within a column can be changed from as described above, however the overall concept of alternating between the central column and a peripheral column with each subsequent therapy pulse sequence delivery can be maintained. It is also desirable to re-excite each focal location within the central column once before repeating the process. For example, focal locations 804a, 804c, and 804e should all be re-excited in some pre-determined order, instead of re-exciting focal location 804a twice before re-exciting focal location 804c once.
Generally, it is desirable to alternate between a single peripheral or outer column and the central column, until all points in both columns have been excited/re-excited, before moving on to a different peripheral column/central column pair. However, it should be understood that other embodiments can include electronically steering between columns without exciting/re-exciting all focal locations in each peripheral column.
The rapid electronic beam-steering concepts described and shown herein serve to advantageously account for residual cavitation nuclei to enhance treatment of a discrete target location by creating an enhanced excitation volume with overlapping or adjacent focal zones.
In the example of
The time to return to a given focal location for additional therapy pulses can also be adjusted or controlled for to account for residual cavitation nuclei. In one embodiment, the following equation can be used to determine the timing of steering the beam between focal locations and/or returning to previously treated focal locations:
As described in the equation, for some embodiments and focal locations, the time to return to a given focal location can equal the number of unique focal locations (e.g., three focal locations) divided by the pulse repetition frequency (PRF) of the pulse.
As described above, a therapy pulse of a given pulse sequence delivered to each focal location can be a shocked scattering pulse that can include a peak positive half cycle, followed by a peak negative half cycle, followed by a trailing peak positive half cycle. This pulse is generally responsible for forming cavitation at each focal location.
In some embodiments, the specific pulse can include one or more low amplitude pulses following the therapy pulses that are designed and configured to manipulate, push, interact with, or suppress residual cavitation nuclei. In one embodiment, these additional pulses can comprise one, two, or more low amplitude pulses. These low amplitude pulses can have an amplitude that is substantially smaller than the amplitude of the therapy pulse(s). In some embodiments, the low amplitude pulses are designed and configured to push or flush out residual cavitation nuclei from previously treated focal locations. In other embodiments, the low amplitude pulses are designed and configured to spatially modulate cavitation nuclei within the previously treated focal location. For example, referring to
The embodiment of
Therapy Components
The Therapy sub-system may work with other sub-systems to create, optimize, deliver, visualize, monitor and control acoustic cavitation, also referred to herein and in following as “histotripsy”, and its derivatives of, including boiling histotripsy and other thermal high frequency ultrasound approaches. It is noted that the disclosed inventions may also further benefit other acoustic therapies that do not comprise a cavitation, mechanical or histotripsy component. The therapy sub-system can include, among other features, an ultrasound therapy transducer and a pulse generator system configured to deliver ultrasound pulses into tissue.
In order to create and deliver histotripsy and derivatives of histotripsy, the therapy sub-system may also comprise components, including but not limited to, one or more function generators, amplifiers, therapy transducers and power supplies.
The therapy transducer can comprise a single element or multiple elements configured to be excited with high amplitude electric pulses (>1000 V or any other voltage that can cause harm to living organisms). The amplitude necessary to drive the therapy transducers for Histotripsy vary depending on the design of the transducer and the materials used (e.g., solid or polymer/piezoelectric composite including ceramic or single crystal) and the transducer center frequency which is directly proportional to the thickness of the piezo-electric material. Transducers therefore operating at a high frequency require lower voltage to produce a given surface pressure than is required by low frequency therapy transducers. In some embodiments, the transducer elements are formed using a piezoelectric-polymer composite material or a solid piezoelectric material. Further, the piezoelectric material can be of polycrystalline/ceramic or single crystalline formulation. In some embodiments the transducer elements can be formed using silicon using MEMs technology, including CMUT and PMUT designs.
In some embodiments, the function generator may comprise a field programmable gate array (FPGA) or other suitable function generator. The FPGA may be configured with parameters disclosed previously herein, including but not limited to frequency, pulse repetition frequency, bursts, burst numbers, where bursts may comprise pulses, numbers of pulses, length of pulses, pulse period, delays, burst repetition frequency or period, where sets of bursts may comprise a parameter set, where loop sets may comprise various parameter sets, with or without delays, or varied delays, where multiple loop sets may be repeated and/or new loop sets introduced, of varied time delay and independently controlled, and of various combinations and permutations of such, overall and throughout.
In some embodiments, the generator or amplifier may be configured to be a universal single-cycle or multi-cycle pulse generator, and to support driving via Class D or inductive driving, as well as across all envisioned clinical applications, use environments, also discussed in part later in this disclosure. In other embodiments, the class D or inductive current driver may be configured to comprise transformer and/or auto-transformer driving circuits to further provide step up/down components, and in some cases, to preferably allow a step up in the amplitude. They may also comprise specific protective features, to further support the system, and provide capability to protect other parts of the system (e.g., therapy transducer and/or amplifier circuit components) and/or the user, from various hazards, including but not limited to, electrical safety hazards, which may potentially lead to use environment, system and therapy system, and user harms, damage or issues.
Disclosed generators may allow and support the ability of the system to select, vary and control various parameters (through enabled software tools), including, but not limited to those previously disclosed, as well as the ability to start/stop therapy, set and read voltage level, pulse and/or burst repetition frequency, number of cycles, duty ratio, channel enabled and delay, etc., modulate pulse amplitude on a fast time-scale independent of a high voltage supply, and/or other service, diagnostic or treatment features.
In some embodiments, the Therapy sub-system and/or components of, such as the amplifier, may comprise further integrated computer processing capability and may be networked, connected, accessed, and/or be removable/portable, modular, and/or exchangeable between systems, and/or driven/commanded from/by other systems, or in various combinations. Other systems may include other acoustic cavitation/histotripsy, HIFU, HITU, radiation therapy, radiofrequency, microwave, and cryoablation systems, navigation and localization systems, open surgical, laparoscopic, single incision/single port, endoscopic and non-invasive surgical robots, laparoscopic or surgical towers comprising other energy-based or vision systems, surgical system racks or booms, imaging carts, etc.
In some embodiments, one or more amplifiers may comprise a Class D amplifier and related drive circuitry including matching network components. Depending on the transducer element electric impedance and choice of the matching network components (e.g., an LC circuit made of an inductor L1 in series and the capacitor C1 in parallel), the combined impedance can be aggressively set low in order to have high amplitude electric waveform necessary to drive the transducer element. The maximum amplitude that Class D amplifiers is dependent on the circuit components used, including the driving MOSFET/IGBT transistors, matching network components or inductor, and transformer or autotransformer, and of which may be typically in the low kV (e.g., 1-3 kV) range.
Therapy transducer element(s) are excited with an electrical waveform with an amplitude (voltage) to produce a pressure output sufficient for Histotripsy therapy. The excitation electric field can be defined as the necessary waveform voltage per thickness of the piezoelectric element. For example, because a piezoelectric element operating at 1 MHz transducer is half the thickness of an equivalent 500 kHz element, it will require half the voltage to achieve the same electric field and surface pressure.
The Therapy sub-system may also comprise therapy transducers of various designs and working parameters, supporting use in various procedures (and procedure settings). Systems may be configured with one or more therapy transducers, that may be further interchangeable, and work with various aspects of the system in similar or different ways (e.g., may interface to a robotic arm using a common interface and exchange feature, or conversely, may adapt to work differently with application specific imaging probes, where different imaging probes may interface and integrate with a therapy transducer in specifically different ways).
Therapy transducers may be configured of various parameters that may include size, shape (e.g., rectangular or round; anatomically curved housings, etc.), geometry, focal length, number of elements, size of elements, distribution of elements (e.g., number of rings, size of rings for annular patterned transducers), frequency, enabling electronic beam steering, etc. Transducers may be composed of various materials (e.g., piezoelectric, silicon, etc.), form factors and types (e.g., machined elements, chip-based, etc.) and/or by various methods of fabrication of.
Transducers may be designed and optimized for clinical applications (e.g., abdominal tumors, peripheral vascular disease, fat ablation, etc.) and desired outcomes (e.g., acoustic cavitation/histotripsy without thermal injury to intervening tissue), and affording a breadth of working ranges, including relatively shallow and superficial targets (e.g., thyroid or breast nodules), versus, deeper or harder to reach targets, such as central liver or brain tumors. They may be configured to enable acoustic cavitation/histotripsy under various parameters and sets of, as enabled by the aforementioned system components (e.g., function generator and amplifier, etc.), including but not limited to frequency, pulse repetition rate, pulses, number of pulses, pulse length, pulse period, delays, repetitions, sync delays, sync period, sync pulses, sync pulse delays, various loop sets, others, and permutations of. The transducer may also be designed to allow for the activation of a drug payload either deposited in tissue through various means including injection, placement or delivery in micelle or nanostructures.
Integrated Imaging
The disclosed system may comprise various imaging modalities to allow users to visualize, monitor and collect/use feedback of the patient's anatomy, related regions of interest and treatment/procedure sites, as well as surrounding and intervening tissues to assess, plan and conduct procedures, and adjust treatment parameters as needed. Imaging modalities may comprise various ultrasound, x-ray, CT, MRI, PET, fluoroscopy, optical, contrast or agent enhanced versions, and/or various combinations of. It is further disclosed that various image processing and characterization technologies may also be utilized to afford enhanced visualization and user decision making. These may be selected or commanded manually by the user or in an automated fashion by the system. The system may be configured to allow side by side, toggling, overlays, 3D reconstruction, segmentation, registration, multi-modal image fusion, image flow, and/or any methodology affording the user to identify, define and inform various aspects of using imaging during the procedure, as displayed in the various system user interfaces and displays. Examples may include locating, displaying and characterizing regions of interest, organ systems, potential treatment sites within, with on and/or surrounding organs or tissues, identifying critical structures such as ducts, vessels, nerves, ureters, fissures, capsules, tumors, tissue trauma/injury/disease, other organs, connective tissues, etc., and/or in context to one another, of one or more (e.g., tumor draining lymphatics or vasculature; or tumor proximity to organ capsule or underlying other organ), as unlimited examples.
Systems may be configured to include onboard integrated imaging hardware, software, sensors, probes and wetware, and/or may be configured to communicate and interface with external imaging and image processing systems. The aforementioned components may be also integrated into the system's Therapy sub-system components wherein probes, imaging arrays, or the like, and electrically, mechanically or electromechanically integrated into therapy transducers. This may afford, in part, the ability to have geometrically aligned imaging and therapy, with the therapy directly within the field of view, and in some cases in line, with imaging. In some embodiments, this integration may comprise a fixed orientation of the imaging capability (e.g., imaging probe) in context to the therapy transducer. In other embodiments, the imaging solution may be able to move or adjust its position, including modifying angle, extension (e.g., distance from therapy transducer or patient), rotation (e.g., imaging plane in example of an ultrasound probe) and/or other parameters, including moving/adjusting dynamically while actively imaging. The imaging component or probe may be encoded so its orientation and position relative to another aspect of the system, such as the therapy transducer, and/or robotically-enabled positioning component may be determined.
In one embodiment, the system may comprise onboard ultrasound, further configured to allow users to visualize, monitor and receive feedback for procedure sites through the system displays and software, including allowing ultrasound imaging and characterization (and various forms of), ultrasound guided planning and ultrasound guided treatment, all in real-time. The system may be configured to allow users to manually, semi-automated or in fully automated means image the patient (e.g., by hand or using a robotically-enabled imager).
In some embodiments, imaging feedback and monitoring can include monitoring changes in: backscatter from bubble clouds; speckle reduction in backscatter; backscatter speckle statistics; mechanical properties of tissue (i.e., elastography); tissue perfusion (i.e., ultrasound contrast); shear wave propagation; acoustic emissions, electrical impedance tomography, and/or various combinations of, including as displayed or integrated with other forms of imaging (e.g., CT or MRI).
In some embodiments, imaging including feedback and monitoring from backscatter from bubble clouds, may be used as a method to determine immediately if the histotripsy process has been initiated, is being properly maintained, or even if it has been extinguished. For example, this method enables continuously monitored in real time drug delivery, tissue erosion, and the like. The method also can provide feedback permitting the histotripsy process to be initiated at a higher intensity and maintained at a much lower intensity. For example, backscatter feedback can be monitored by any transducer or ultrasonic imager. By measuring feedback for the therapy transducer, an accessory transducer can send out interrogation pulses or be configured to passively detect cavitation. Moreover, the nature of the feedback received can be used to adjust acoustic parameters (and associated system parameters) to optimize the drug delivery and/or tissue erosion process.
In some embodiments, imaging including feedback and monitoring from backscatter, and speckle reduction, may be configured in the system.
For systems comprising feedback and monitoring via backscattering, and as means of background, as tissue is progressively mechanically subdivided, in other words homogenized, disrupted, or eroded tissue, this process results in changes in the size and distribution of acoustic scatter. At some point in the process, the scattering particle size and density is reduced to levels where little ultrasound is scattered, or the amount scattered is reduced significantly. This results in a significant reduction in speckle, which is the coherent constructive and destructive interference patterns of light and dark spots seen on images when coherent sources of illumination are used; in this case, ultrasound. After some treatment time, the speckle reduction results in a dark area in the therapy volume. Since the amount of speckle reduction is related to the amount of tissue subdivision, it can be related to the size of the remaining tissue fragments. When this size is reduced to sub-cellular levels, no cells are assumed to have survived. So, treatment can proceed until a desired speckle reduction level has been reached. Speckle is easily seen and evaluated on standard ultrasound imaging systems. Specialized transducers and systems, including those disclosed herein, may also be used to evaluate the backscatter changes.
Further, systems comprising feedback and monitoring via speckle, and as means of background, an image may persist from frame to frame and change very little as long as the scatter distribution does not change and there is no movement of the imaged object. However, long before the scatters are reduced enough in size to cause speckle reduction, they may be changed sufficiently to be detected by signal processing and other means. This family of techniques can operate as detectors of speckle statistics changes. For example, the size and position of one or more speckles in an image will begin to decorrelate before observable speckle reduction occurs. Speckle decorrelation, after appropriate motion compensation, can be a sensitive measure of the mechanical disruption of the tissues, and thus a measure of therapeutic efficacy. This feedback and monitoring technique may permit early observation of changes resulting from the acoustic cavitation/histotripsy process and can identify changes in tissue before substantial or complete tissue effect (e.g., erosion occurs). In one embodiment, this method may be used to monitor the acoustic cavitation/histotripsy process for enhanced drug delivery where treatment sites/tissue is temporally disrupted, and tissue damage/erosion is not desired. In other embodiments, this may comprise speckle decorrelation by movement of scatters in an increasingly fluidized therapy volume. For example, in the case where partial or complete tissue erosion is desired.
For systems comprising feedback and monitoring via elastography, and as means of background, as treatment sites/tissue are further subdivided per an acoustic cavitation/histotripsy effect (homogenized, disrupted, or eroded), its mechanical properties change from a soft but interconnected solid to a viscous fluid or paste with few long-range interactions. These changes in mechanical properties can be measured by various imaging modalities including MRI and ultrasound imaging systems. For example, an ultrasound pulse can be used to produce a force (i.e., a radiation force) on a localized volume of tissue. The tissue response (displacements, strains, and velocities) can change significantly during histotripsy treatment allowing the state of tissue disruption to be determined by imaging or other quantitative means.
Systems may also comprise feedback and monitoring via shear wave propagation changes. As means of background, the subdivision of tissues makes the tissue more fluid and less solid and fluid systems generally do not propagate shear waves. Thus, the extent of tissue fluidization provides opportunities for feedback and monitoring of the histotripsy process. For example, ultrasound and MRI imaging systems can be used to observe the propagation of shear waves. The extinction of such waves in a treated volume is used as a measure of tissue destruction or disruption. In one system embodiment, the system and supporting sub-systems may be used to generate and measure the interacting shear waves. For example, two adjacent ultrasound foci might perturb tissue by pushing it in certain ways. If adjacent foci are in a fluid, no shear waves propagate to interact with each other. If the tissue is not fluidized, the interaction would be detected with external means, for example, by a difference frequency only detected when two shear waves interact nonlinearly, with their disappearance correlated to tissue damage. As such, the system may be configured to use this modality to enhance feedback and monitoring of the acoustic cavitation/histotripsy procedure.
For systems comprising feedback and monitoring via acoustic emission, and as means of background, as a tissue volume is subdivided, its effect on acoustic cavitation/histotripsy (e.g., the bubble cloud here) is changed. For example, bubbles may grow larger and have a different lifetime and collapse changing characteristics in intact versus fluidized tissue. Bubbles may also move and interact after tissue is subdivided producing larger bubbles or cooperative interaction among bubbles, all of which can result in changes in acoustic emission. These emissions can be heard during treatment and they change during treatment. Analysis of these changes, and their correlation to therapeutic efficacy, enables monitoring of the progress of therapy, and may be configured as a feature of the system.
For systems comprising feedback and monitoring via electrical impedance tomography, and as means of background, an impedance map of a therapy site can be produced based upon the spatial electrical characteristics throughout the therapy site. Imaging of the conductivity or permittivity of the therapy site of a patient can be inferred from taking skin surface electrical measurements. Conducting electrodes are attached to a patient's skin and small alternating currents are applied to some or all of the electrodes. One or more known currents are injected into the surface and the voltage is measured at a number of points using the electrodes. The process can be repeated for different configurations of applied current. The resolution of the resultant image can be adjusted by changing the number of electrodes employed. A measure of the electrical properties of the therapy site within the skin surface can be obtained from the impedance map, and changes in and location of the acoustic cavitation/histotripsy (e.g., bubble cloud, specifically) and histotripsy process can be monitored using this as configured in the system and supporting sub-systems.
The user may be allowed to further select, annotate, mark, highlight, and/or contour, various regions of interest or treatment sites, and defined treatment targets (on the image(s)), of which may be used to command and direct the system where to image, test and/or treat, through the system software and user interfaces and displays. In some arrangements, the user may use a manual ultrasound probe (e.g., diagnostic hand-held probe) to conduct the procedure. In another arrangement, the system may use a robot and/or electromechanical positioning system to conduct the procedure, as directed and/or automated by the system, or conversely, the system can enable combinations of manual and automated uses.
The system may further include the ability to conduct image registration, including imaging and image data set registration to allow navigation and localization of the system to the patient, including the treatment site (e.g., tumor, critical structure, bony anatomy, anatomy and identifying features of, etc.). In one embodiment, the system allows the user to image and identify a region of interest, for example the liver, using integrated ultrasound, and to select and mark a tumor (or surrogate marker of) comprised within the liver through/displayed in the system software, and wherein said system registers the image data to a coordinate system defined by the system, that further allows the system's Therapy and Robotics sub-systems to deliver synchronized acoustic cavitation/histotripsy to said marked tumor. The system may comprise the ability to register various image sets, including those previously disclosed, to one another, as well as to afford navigation and localization (e.g., of a therapy transducer to a CT or MRI/ultrasound fusion image with the therapy transducer and Robotics sub-system tracking to said image).
The system may also comprise the ability to work in a variety of interventional, endoscopic and surgical environments, including alone and with other systems (surgical/laparoscopic towers, vision systems, endoscope systems and towers, ultrasound enabled endoscopic ultrasound (flexible and rigid), percutaneous/endoscopic/laparoscopic and minimally invasive navigation systems (e.g., optical, electromagnetic, shape-sensing, ultrasound-enabled, etc.), of also which may work with, or comprise various optical imaging capabilities (e.g., fiber and or digital). The disclosed system may be configured to work with these systems, in some embodiments working alongside them in concert, or in other embodiments where all or some of the system may be integrated into the above systems/platforms (e.g., acoustic cavitation/histotripsy-enabled endoscope system or laparoscopic surgical robot). In many of these environments, a therapy transducer may be utilized at or around the time of use, for example, of an optically guided endoscope/bronchoscope, or as another example, at the time a laparoscopic robot (e.g., Intuitive Da Vinci* Xi system) is viewing/manipulating a tissue/treatment site. Further, these embodiments and examples may include where said other systems/platforms are used to deliver (locally) fluid to enable the creation of a man-made acoustic window, where on under normal circumstances may not exist (e.g., fluidizing a segment or lobe of the lung in preparation for acoustic cavitation/histotripsy via non-invasive transthoracic treatment (e.g., transducer externally placed on/around patient). Systems disclosed herein may also comprise all or some of their sub-system hardware packaged within the other system cart/console/systems described here (e.g., acoustic cavitation/histotripsy system and/or sub-systems integrated and operated from said navigation or laparoscopic system).
The system may also be configured, through various aforementioned parameters and other parameters, to display real-time visualization of a bubble cloud in a spatial-temporal manner, including the resulting tissue effect peri/post-treatment from tissue/bubble cloud interaction, wherein the system can dynamically image and visualize, and display, the bubble cloud, and any changes to it (e.g., decreasing or increasing echogenicity), which may include intensity, shape, size, location, morphology, persistence, etc. These features may allow users to continuously track and follow the treatment in real-time in one integrated procedure and interface/system, and confirm treatment safety and efficacy on the fly (versus other interventional or surgical modalities, which either require multiple procedures to achieve the same, or where the treatment effect is not visible in real-time (e.g., radiation therapy), or where it is not possible to achieve such (e.g., real-time visualization of local tissue during thermal ablation), and/or where the other procedure further require invasive approaches (e.g., incisions or punctures) and iterative imaging in a scanner between procedure steps (e.g., CT or MRI scanning). The above disclosed systems, sub-systems, components, modalities, features and work-flows/methods of use may be implemented in an unlimited fashion through enabling hardware, software, user interfaces and use environments, and future improvements, enhancements and inventions in this area are considered as included in the scope of this disclosure, as well as any of the resulting data and means of using said data for analytics, artificial intelligence or digital health applications and systems.
Robotics
They system may comprise various Robotic sub-systems and components, including but not limited to, one or more robotic arms and controllers, which may further work with other sub-systems or components of the system to deliver and monitor acoustic cavitation/histotripsy. As previously discussed herein, robotic arms and control systems may be integrated into one or more Cart configurations.
For example, one system embodiment may comprise a Cart with an integrated robotic arm and control system, and Therapy, Integrated Imaging and Software, where the robotic arm and other listed sub-systems are controlled by the user through the form factor of a single bedside Cart.
In other embodiments, the Robotic sub-system may be configured in one or more separate Carts, that may be a driven in a master/slave configuration from a separate master or Cart, wherein the robotically-enabled Cart is positioned bed/patient-side, and the Master is at a distance from said Cart.
Disclosed robotic arms may be comprised of a plurality of joints, segments, and degrees of freedom and may also include various integrated sensor types and encoders, implemented for various use and safety features. Sensing technologies and data may comprise, as an example, vision, potentiometers, position/localization, kinematics, force, torque, speed, acceleration, dynamic loading, and/or others. In some cases, sensors may be used for users to direct robot commands (e.g., hand gesture the robot into a preferred set up position, or to dock home). Additional details on robotic arms can be found in US Patent Pub. No. 2013/0255426 to Kassow et al. which is disclosed herein by reference in its entirety.
The robotic arm receives control signals and commands from the robotic control system, which may be housed in a Cart. The system may be configured to provide various functionalities, including but not limited to, position, tracking, patterns, triggering, and events/actions.
Position may be configured to comprise fixed positions, pallet positions, time-controlled positions, distance-controlled positions, variable-time controlled positions, variable-distance controlled positions.
Tracking may be configured to comprise time-controlled tracking and/or distance-controlled tracking.
The patterns of movement may be configured to comprise intermediate positions or waypoints, as well as sequence of positions, through a defined path in space.
Triggers may be configured to comprise distance measuring means, time, and/or various sensor means including those disclosed herein, and not limited to, visual/imaging-based, force, torque, localization, energy/power feedback and/or others.
Events/actions may be configured to comprise various examples, including proximity-based (approaching/departing a target object), activation or de-activation of various end-effectors (e.g., therapy transducers), starting/stopping/pausing sequences of said events, triggering or switching between triggers of events/actions, initiating patterns of movement and changing/toggling between patterns of movement, and/or time-based and temporal over the defined work and time-space.
In one embodiment, the system comprises a three degree of freedom robotic positioning system, enabled to allow the user (through the software of the system and related user interfaces), to micro-position a therapy transducer through X, Y, and Z coordinate system, and where gross macro-positioning of the transducer (e.g., aligning the transducer on the patient's body) is completed manually. In some embodiments, the robot may comprise 6 degrees of freedom including X, Y, Z, and pitch, roll and yaw. In other embodiments, the Robotic sub-system may comprise further degrees of freedom, that allow the robot arm supporting base to be positioned along a linear axis running parallel to the general direction of the patient surface, and/or the supporting base height to be adjusted up or down, allowing the position of the robotic arm to be modified relative to the patient, patient surface, Cart, Coupling sub-system, additional robots/robotic arms and/or additional surgical systems, including but not limited to, surgical towers, imaging systems, endoscopic/laparoscopic systems, and/or other.
One or more robotic arms may also comprise various features to assist in maneuvering and modifying the arm position, manually or semi-manually, and of which said features may interface on or between the therapy transducer and the most distal joint of the robotic arm. In some embodiments, the feature is configured to comprise a handle allowing maneuvering and manual control with one or more hands. The handle may also be configured to include user input and electronic control features of the robotic arm, to command various drive capabilities or modes, to actuate the robot to assist in gross or fine positioning of the arm (e.g., activating or deactivating free drive mode). The work-flow for the initial positioning of the robotic arm and therapy head can be configured to allow either first positioning the therapy transducer/head in the coupling solution, with the therapy transducer directly interfaced to the arm, or in a different work-flow, allowing the user to set up the coupling solution first, and enabling the robot arm to be interfaced to the therapy transducer/coupling solution as a later/terminal set up step.
In some embodiments, the robotic arm may comprise a robotic arm on a laparoscopic, single port, endoscopic, hybrid or combination of, and/or other robot, wherein said robot of the system may be a slave to a master that controls said arm, as well as potentially a plurality of other arms, equipped to concurrently execute other tasks (vision, imaging, grasping, cutting, ligating, sealing, closing, stapling, ablating, suturing, marking, etc.), including actuating one or more laparoscopic arms (and instruments) and various histotripsy system components. For example, a laparoscopic robot may be utilized to prepare the surgical site, including manipulating organ position to provide more ideal acoustic access and further stabilizing said organ in some cases to minimize respiratory motion. In conjunction and parallel to this, a second robotic arm may be used to deliver non-invasive acoustic cavitation through a body cavity, as observed under real-time imaging from the therapy transducer (e.g., ultrasound) and with concurrent visualization via a laparoscopic camera. In other related aspects, a similar approach may be utilized with a combination of an endoscopic and non-invasive approach, and further, with a combination of an endoscopic, laparoscopic and non-invasive approach.
Software
The system may comprise various software applications, features and components which allow the user to interact, control and use the system for a plethora of clinical applications. The Software may communicate and work with one or more of the sub-systems, including but not limited to Therapy, Integrated Imaging, Robotics and Other Components, Ancillaries and Accessories of the system.
Overall, in no specific order of importance, the software may provide features and support to initialize and set up the system, service the system, communicate and import/export/store data, modify/manipulate/configure/control/command various settings and parameters by the user, mitigate safety and use-related risks, plan procedures, provide support to various configurations of transducers, robotic arms and drive systems, function generators and amplifier circuits/slaves, test and treatment ultrasound sequences, transducer steering and positioning (electromechanical and electronic beam steering, etc.), treatment patterns, support for imaging and imaging probes, manual and electromechanical/robotically-enabling movement of, imaging support for measuring/characterizing various dimensions within or around procedure and treatment sites (e.g., depth from one anatomical location to another, etc., pre-treatment assessments and protocols for measuring/characterizing in situ treatment site properties and conditions (e.g., acoustic cavitation/histotripsy thresholds and heterogeneity of), targeting and target alignment, calibration, marking/annotating, localizing/navigating, registering, guiding, providing and guiding through work-flows, procedure steps, executing treatment plans and protocols autonomously, autonomously and while under direct observation and viewing with real-time imaging as displayed through the software, including various views and viewports for viewing, communication tools (video, audio, sharing, etc.), troubleshooting, providing directions, warnings, alerts, and/or allowing communication through various networking devices and protocols. It is further envisioned that the software user interfaces and supporting displays may comprise various buttons, commands, icons, graphics, text, etc., that allow the user to interact with the system in a user-friendly and effective manner, and these may be presented in an unlimited number of permutations, layouts and designs, and displayed in similar or different manners or feature sets for systems that may comprise more than one display (e.g., touch screen monitor and touch pad), and/or may network to one or more external displays or systems (e.g., another robot, navigation system, system tower, console, monitor, touch display, mobile device, tablet, etc.).
The software, as a part of a representative system, including one or more computer processors, may support the various aforementioned function generators (e.g., FPGA), amplifiers, power supplies and therapy transducers. The software may be configured to allow users to select, determine and monitor various parameters and settings for acoustic cavitation/histotripsy, and upon observing/receiving feedback on performance and conditions, may allow the user to stop/start/modify said parameters and settings.
The software may be configured to allow users to select from a list or menu of multiple transducers and support the auto-detection of said transducers upon connection to the system (and verification of the appropriate sequence and parameter settings based on selected application). In other embodiments, the software may update the targeting and amplifier settings (e.g., channels) based on the specific transducer selection. The software may also provide transducer recommendations based on pre-treatment and planning inputs. Conversely, the software may provide error messages or warnings to the user if said therapy transducer, amplifier and/or function generator selections or parameters are erroneous, yield a fault or failure. This may further comprise reporting the details and location of such.
In addition to above, the software may be configured to allow users to select treatment sequences and protocols from a list or menu, and to store selected and/or previous selected sequences and protocols as associated with specific clinical uses or patient profiles. Related profiles may comprise any associated patient, procedure, clinical and/or engineering data, and maybe used to inform, modify and/or guide current or future treatments or procedures/interventions, whether as decision support or an active part of a procedure itself (e.g., using serial data sets to build and guide new treatments).
As a part of planning or during the treatment, the software (and in working with other components of the system) may allow the user to evaluate and test acoustic cavitation/histotripsy thresholds at various locations in a user-selected region of interest or defined treatment area/volume, to determine the minimum cavitation thresholds throughout said region or area/volume, to ensure treatment parameters are optimized to achieve, maintain and dynamically control acoustic cavitation/histotripsy. In one embodiment, the system allows a user to manually evaluate and test threshold parameters at various points. Said points may include those at defined boundary, interior to the boundary and center locations/positions, of the selected region of interest and treatment area/volume, and where resulting threshold measurements may be reported/displayed to the user, as well as utilized to update therapy parameters before treatment. In another embodiment, the system may be configured to allow automated threshold measurements and updates, as enabled by the aforementioned Robotics sub-system, wherein the user may direct the robot, or the robot may be commanded to execute the measurements autonomously.
Software may also be configured, by working with computer processors and one or more function generators, amplifiers and therapy transducers, to allow various permutations of delivering and positioning optimized acoustic cavitation/histotripsy in and through a selected area/volume. This may include, but not limited to, systems configured with a fixed/natural focus arrangement using purely electromechanical positioning configuration(s), electronic beam steering (with or without electromechanical positioning), electronic beam steering to a new selected fixed focus with further electromechanical positioning, axial (Z axis) electronic beam steering with lateral (X and Y) electromechanical positioning, high speed axial electronic beam steering with lateral electromechanical positioning, high speed beam steering in 3D space, various combinations of including with dynamically varying one or more acoustic cavitation/histotripsy parameters based on the aforementioned ability to update treatment parameters based on threshold measurements (e.g., dynamically adjusting amplitude across the treatment area/volume).
Other Components, Ancillaries and Accessories
The system may comprise various other components, ancillaries and accessories, including but not limited to computers, computer processors, power supplies including high voltage power supplies, controllers, cables, connectors, networking devices, software applications for security, communication, integration into information systems including hospital information systems, cellular communication devices and modems, handheld wired or wireless controllers, goggles or glasses for advanced visualization, augmented or virtual reality applications, cameras, sensors, tablets, smart devices, phones, internet of things enabling capabilities, specialized use “apps” or user training materials and applications (software or paper based), virtual proctors or trainers and/or other enabling features, devices, systems or applications, and/or methods of using the above.
System Variations and Methods/Applications
In addition to performing a breadth of procedures, the system may allow additional benefits, such as enhanced planning, imaging and guidance to assist the user. In one embodiment, the system may allow a user to create a patient, target and application specific treatment plan, wherein the system may be configured to optimize treatment parameters based on feedback to the system during planning, and where planning may further comprise the ability to run various test protocols to gather specific inputs to the system and plan.
Feedback may include various energy, power, location, position, tissue and/or other parameters.
The system, and the above feedback, may also be further configured and used to autonomously (and robotically) execute the delivery of the optimized treatment plan and protocol, as visualized under real-time imaging during the procedure, allowing the user to directly observe the local treatment tissue effect, as it progresses through treatment, and start/stop/modify treatment at their discretion. Both test and treatment protocols may be updated over the course of the procedure at the direction of the user, or in some embodiments, based on logic embedded within the system.
It is also recognized that many of these benefits may further improve other forms of acoustic therapy, including thermal ablation with high intensity focused ultrasound (HIFU), high intensity therapeutic ultrasound (HITU) including boiling histotripsy (thermal cavitation), and are considered as part of this disclosure. The disclosure also considers the application of histotripsy as a means to activate previously delivered in active drug payloads whose activity is inert due to protection in a micelle, nanostructure or similar protective structure or through molecular arrangement that allows activation only when struck with acoustic energy.
In another aspect, the Therapy sub-system, comprising in part, one or more amplifiers, transducers and power supplies, may be configured to allow multiple acoustic cavitation and histotripsy driving capabilities, affording specific benefits based on application, method and/or patient specific use. These benefits may include, but are not limited to, the ability to better optimize and control treatment parameters, which may allow delivery of more energy, with more desirable thermal profiles, increased treatment speed and reduced procedure times, enable electronic beam steering and/or other features.
This disclosure also includes novel systems and concepts as related to systems and sub-systems comprising new and “universal” amplifiers, which may allow multiple driving approaches (e.g., single and multi-cycle pulsing). In some embodiments, this may include various novel features to further protect the system and user, in terms of electrical safety or other hazards (e.g., damage to transducer and/or amplifier circuitry).
In another aspect, the system, and Therapy sub-system, may include a plethora of therapy transducers, where said therapy transducers are configured for specific applications and uses and may accommodate treating over a wide range of working parameters (target size, depth, location, etc.) and may comprise a wide range of working specifications (detailed below). Transducers may further adapt, interface and connect to a robotically-enabled system, as well as the Coupling sub-system, allowing the transducer to be positioned within, or along with, an acoustic coupling device allowing, in many embodiments, concurrent imaging and histotripsy treatments through an acceptable acoustic window. The therapy transducer may also comprise an integrated imaging probe or localization sensors, capable of displaying and determining transducer position within the treatment site and affording a direct field of view (or representation of) the treatment site, and as the acoustic cavitation/histotripsy tissue effect and bubble cloud may or may not change in appearance and intensity, throughout the treatment, and as a function of its location within said treatment (e.g., tumor, healthy tissue surrounding, critical structures, adipose tissue, etc.).
The systems, methods and use of the system disclosed herein, may be beneficial to overcoming significant unmet needs in the areas of soft tissue ablation, oncology, immuno-oncology, advanced image guided procedures, surgical procedures including but not limited to open, laparoscopic, single incision, natural orifice, endoscopic, non-invasive, various combination of, various interventional spaces for catheter-based procedures of the vascular, cardiovascular pulmonary and/or neurocranial-related spaces, cosmetics/aesthetics, metabolic (e.g., type 2 diabetes), plastic and reconstructive, ocular and ophthalmology, orthopedic, gynecology and men's health, and other systems, devices and methods of treating diseased, injured, undesired, or healthy tissues, organs or cells.
Systems and methods are also provided for improving treatment patterns within tissue that can reduce treatment time, improve efficacy, and reduce the amount of energy and prefoc al tissue heating delivered to patients.
Use Environments
The disclosed system, methods of use, and use of the system, may be conducted in a plethora of environments and settings, with or without various support systems such as anesthesia, including but not limited to, procedure suites, operating rooms, hybrid rooms, in and out-patient settings, ambulatory settings, imaging centers, radiology, radiation therapy, oncology, surgical and/or any medical center, as well as physician offices, mobile healthcare centers or systems, automobiles and related vehicles (e.g., van), aero and marine transportation vehicles such as planes and ships, and/or any structure capable of providing temporary procedure support (e.g., tent). In some cases, systems and/or sub-systems disclosed herein may also be provided as integrated features into other environments, for example, the direct integration of the histotripsy Therapy sub-system into a MRI scanner or patient surface/bed, wherein at a minimum the therapy generator and transducer are integral to such, and in other cases wherein the histotripsy configuration further includes a robotic positioning system, which also may be integral to a scanner or bed centered design.
Coupling
Systems may comprise a variety of Coupling sub-system embodiments, of which are enabled and configured to allow acoustic coupling to the patient to afford effective acoustic access for ultrasound visualization and acoustic cavitation/histotripsy (e.g., provide acoustic window and medium between the transducer(s) and patient, and support of). These may include different form factors of such, including open and enclosed device solutions, and some arrangements which may be configured to allow dynamic control over the acoustic medium (e.g., temperature, dissolved gas content, level of particulate filtration, sterility, volume, composition, etc.). Such dynamic control components may be directly integrated to the system (within the Cart), or may be in temporary/intermittent or continuous communication with the system, but externally situated in a separate device and/or cart.
The Coupling sub-system typically comprises, at a minimum, coupling medium (e.g., degassed water or water solutions), a reservoir/container to contain said coupling medium, and a support structure (including interfaces to other surfaces or devices). In most embodiments, the coupling medium is water, and wherein the water may be conditioned before or during the procedure (e.g., chilled, degassed, filtered, etc.). Various conditioning parameters may be employed based on the configuration of the system and its intended use/application.
The reservoir or medium container may be formed and shaped to various sizes and shapes, and to adapt/conform to the patient, allow the therapy transducer to engage/access and work within the acoustic medium, per defined and required working space (minimum volume of medium to allow the therapy transducer to be positioned and/or move through one or more treatment positions or patterns, and at various standoffs or depths from the patient, etc.), and wherein said reservoir or medium container may also mechanically support the load, and distribution of the load, through the use of a mechanical and/or electromechanical support structure. As a representative example, this may include a support frame. The container may be of various shapes, sizes, curvatures, and dimensions, and may be comprised of a variety of materials compositions (single, multiple, composites, etc.), of which may vary throughout. In some embodiments, it may comprise features such as films, drapes, membranes, bellows, etc. that may be insertable and removable, and/or fabricated within, of which may be used to conform to the patient and assist in confining/containing the medium within the container. It may further contain various sensors (e.g., volume/fill level), drains (e.g., inlet/outlet), lighting (e.g., LEDs), markings (e.g., fill lines, set up orientations, etc.), text (e.g., labeling), etc.
In one embodiment, the reservoir or medium container contains a sealable frame, of which a membrane and/or film may be positioned within, to afford a conformable means of contacting the reservoir (later comprising the treatment head/therapy transducer) as an interface to the patient, that further provides a barrier to the medium (e.g., water) between the patient and therapy transducer). In other embodiments, the membrane and/or film may comprise an opening, the patient contacting edge of which affords a fluid/mechanical seal to the patient, but in contrast allows medium communication directly with the patient (e.g., direct degassed water interface with patient). The superstructure of the reservoir or medium container in both these examples may further afford the proximal portion of the structure (e.g., top) to be open or enclosed (e.g., to prevent spillage or afford additional features).
Disclosed membranes may be comprised of various elastomers, viscoelastic polymers, thermoplastics, thermoplastic elastomers, thermoset polymers, silicones, urethanes, rigid/flexible co-polymers, block co-polymers, random block co-polymers, etc. Materials may be hydrophilic, hydrophobic, surface modified, coated, extracted, etc., and may also contain various additives to enhance performance, appearance or stability. In some embodiments, the thermoplastic elastomer may be styrene-ethylene-butylene-styrene (SEBS), or other like strong and flexible elastomers. The membrane form factor can be flat or pre-shaped prior to use. In other embodiments, the membrane could be inelastic (i.e., a convex shape) and pressed against the patient's skin to acoustically couple the transducer to the tissue. Systems and methods are further disclosed to control the level of contaminants (e.g., particulates, etc.) on the membrane to maintain the proper level of ultrasound coupling. Too many particulates or contaminants can cause scattering of the ultrasound waves. This can be achieved with removable films or coatings on the outer surfaces of the membrane to protect against contamination.
Said materials may be formed into useful membranes through molding, casting, spraying, ultrasonic spraying, extruding, and/or any other processing methodology that produces useful embodiments. They may be single use or reposable/reusable. They may be provided non-sterile, aseptically cleaned or sterile, where sterilization may comprise any known method, including but not limited to ethylene oxide, gamma, e-beam, autoclaving, steam, peroxide, plasma, chemical, etc. Membranes can be further configured with an outer molded or over molded frame to provide mechanical stability to the membrane during handling including assembly, set up and take down of the coupling sub-system. Various parameters of the membrane can be optimized for this method of use, including thickness, thickness profile, density, formulation (e.g., polymer molecular weight and copolymer ratios, additives, plasticizers, etc.), including optimizing specifically to maximize acoustic transmission properties, including minimizing impact to cavitation initiation threshold values, and/or ultrasound imaging artifacts, including but not limited to membrane reflections, as representative examples.
Open reservoirs or medium containers may comprise various methods of filling, including using pre-prepared medium or water, that may be delivered into the containers, in some cases to a defined specification of water (level of temperature, gas saturation, etc.), or they may comprise additional features integral to the design that allow filling and draining (e.g., ports, valves, hoses, tubing, fittings, bags, pumps, etc.). These features may be further configured into or to interface to other devices, including for example, a fluidics system. In some cases, the fluidics system may be an in-house medium preparation system in a hospital or care setting room, or conversely, a mobile cart-based system which can prepare and transport medium to and from the cart to the medium container, etc.
Enclosed iterations of the reservoir or medium container may comprise various features for sealing, in some embodiments sealing to a proximal/top portion or structure of a reservoir/container, or in other cases where sealing may comprise embodiments that seal to the transducer, or a feature on the transducer housings. Further, some embodiments may comprise the dynamic ability to control the volume of fluid within these designs, to minimize the potential for air bubbles or turbulence in said fluid and to allow for changes in the focal length to the target area without moving the transducer. As such, integrated features allowing fluid communication, and control of, may be provided (ability to provide/remove fluid on demand), including the ability to monitor and control various fluid parameters, some disclosed above. In order to provide this functionality, the overall system, and as part, the Coupling sub-system, may comprise a fluid conditioning system, which may contain various electromechanical devices, systems, power, sensing, computing, pumping, filtering and control systems, etc. The reservoir may also be configured to receive signals that cause it to deform or change shape in a specific and controlled manner to allow the target point to be adjusted without moving the transducer.
Coupling support systems may include various mechanical support devices to interface the reservoir/container and medium to the patient, and the workspace (e.g., bed, floor, etc.). In some embodiments, the support system comprises a mechanical arm with 3 or more degrees of freedom. Said arm may have a proximal interface with one or more locations (and features) of the bed, including but not limited to, the frame, rails, customized rails or inserts, as well as one or more distal locations of the reservoir or container. The arm may also be a feature implemented on one or more Carts, wherein Carts may be configured in various unlimited permutations, in some cases where a Cart only comprises the role of supporting and providing the disclosed support structure.
In some embodiments, the support structure and arm may be a robotically-enabled arm, implemented as a stand-alone Cart, or integrated into a Cart further comprising two or more system sub-systems, or where in the robotically-enabled arm is an arm of another robot, of interventional, surgical or other type, and may further comprise various user input features to actuate/control the robotic arm (e.g., positioning into/within coupling medium) and/or Coupling solution features (e.g., filling, draining, etc.). In some examples, the support structure robotic arm positional encoders may be used to coordinate the manipulation of the second arm (e.g. comprising the therapy transducer/treatment head), such as to position the therapy transducer to a desired/known location and pose within the coupling support structure.
Overall, significant unmet needs exist in interventional and surgical medical procedures today, including those procedures utilizing minimally invasive devices and approaches to treat disease and/or injury, and across various types of procedures where the unmet needs may be solved with entirely new medical procedures. Today's medical system capabilities are often limited by access, wherein a less or non-invasive approach would be preferred, or wherein today's tools aren't capable to deliver preferred/required tissue effects (e.g., operate around/through critical structures without serious injury), or where the physical set up of the systems makes certain procedure approaches less desirable or not possible, and where a combination of approaches, along with enhanced tissue effecting treatments, may enable entirely new procedures and approaches, not possible today.
In addition, specific needs exist for enabling histotripsy delivery, including robotic histotripsy delivery, wherein one or more histotripsy therapy transducers may be configured to acoustically couple to a patient, using a completely sealed approach (e.g., no acoustic medium communication with the patient's skin) and allowing the one or more histotripsy transducers to be moved within the coupling solution without impeding the motion/movement of the robotic arm or interfering/disturbing the coupling interface, which could affect the intended treatment and/or target location.
Disclosed herein are histotripsy acoustic and patient coupling systems and methods, to enable histotripsy therapy/treatment, as envisioned in any setting, from interventional suite, operating room, hybrid suites, imaging centers, medical centers, office settings, mobile treatment centers, and/or others, as non-limiting examples. The following disclosure further describes novel systems used to create, control, maintain, modify/enhance, monitor and setup/takedown acoustic and patient coupling systems, in a variety of approaches, methods, environments, architectures and work-flows. In general, the disclosed novel systems may allow for a coupling medium, in some examples degassed water, to be interfaced between a histotripsy therapy transducer and a patient, wherein the acoustic medium provides sufficient acoustic coupling to said patient, allowing the delivery of histotripsy pulses through a user desired treatment location (and volume), where the delivery may require physically moving the histotripsy therapy transducer within a defined work-space comprising the coupling medium, and also where the coupling system is configured to allow said movement of the therapy transducer (and positioning system, e.g., robot) freely and unencumbered from by the coupling support system (e.g., a frame or manifold holding the coupling medium).
Coupling System and Sub-Systems/Components
The disclosed histotripsy acoustic and patient coupling systems, in general, may comprise one or more of the following sub-systems and components, an example of which is depicted in
In some embodiments, the coupling system may be fully sealed, and in other embodiments and configurations, it may be partially open to afford immediate access (physical and/or visual).
The acoustic and patient coupling systems and sub-systems may further comprise various features and functionality, and associated work-flows, and may also be configured in a variety of ways to enable histotripsy procedures as detailed below.
The therapy and/or imaging transducers can be housed in a coupling assembly 212 which can further include a coupling membrane 214 and a membrane constraint 216 configured to prevent the membrane from expanding too far from the transducer. The coupling membrane can be filled with an acoustic coupling medium such as a fluid or a gel. The membrane constraint can be, for example, a semi-rigid or rigid material configured to restrict expansion/movement of the membrane. In some embodiments, the membrane constraint is not used, and the elasticity and tensile strength of the membrane prevent over expansion. The coupling membrane can be a mineral-oil infused SEBS membrane to prevent direct fluid contact with the patient's skin. In the illustrated embodiment, the coupling assembly 212 is supported by a mechanical support arm 218 which can be load bearing in the x-y plane but allow for manual or automated z-axis adjustment. The mechanical support arm can be attached to the floor, the patient table, or the cart 210. The mechanical support is designed and configured to conform and hold the coupling membrane 214 in place against the patient's skin while still allowing movement of the therapy/imaging transducer relative to the patient and also relative to the coupling membrane 214 with the robotic positioning arm 208.
The system can further include a fluidics system 220 that can include a fluid source, a cooling and degassing system, and a programmable control system. The fluidics system is configured for external loading of the coupling membrane with automated control of fluidic sequences. Further details on the fluidics system 220 are provided below.
Membranes/Barrier Films and Related Architectures
Membranes and barrier films may be composed of various biocompatible materials which allow conformal coupling to patient anatomy with minimal or no entrapped bubbles capable of interfering with ultrasound imaging and histotripsy therapy, and that are capable of providing a sealed barrier layer between said patient anatomy and the ultrasound medium, of which is contained within the work-space provided by the frame and assembly.
Membrane and barrier film materials may comprise flexible and elastomeric biocompatible materials/polymers, such as various thermoplastic and thermoset materials, as well as permanent or bioresorbable polymers. Additionally, the frame of the UMC can also comprise the same materials. In some examples, the membrane may be rigid or semi-rigid polymers which are pre-shaped or flat.
Ultrasound Medium
As previously described, the ultrasound medium may comprise any applicable medium capable of providing sufficient and useful acoustic coupling to allow histotripsy treatments and enable sufficient clinical imaging (e.g., ultrasound). Ultrasound mediums, as a part of this disclosure and system, may comprise, but are not limited to, various aqueous solutions/mediums, including mixtures with other co-soluble fluids, of which may have preferred or more preferred acoustic qualities, including ability to match speed of sound, etc. Example mediums may comprise degassed water and/or mixtures/co-solutions of degassed water and various alcohols, such as ethanol.
Mechanical Support Arms and Arm Architectures
In order to support the acoustic and patient coupling system, including providing efficient and ergonomic work-flows for users, various designs and configurations of mechanical support arms (and arm architectures) may be employed. Support arms may be configured with a range of degrees of freedom, including but not limited to allowing, x, y, z, pitch, roll and yaw, as well additional interfacing features that may allow additional height adjustment or translation.
Arms may comprise a varied number and type of joints and segments. Typically, arms may comprise a minimum of 2 segments. In some configurations, arms may comprise 3 to 5 segments.
Arms are also be configured to interface proximally to a main support base or base interface (e.g., robot, table, table/bed rail, cart, floor mount, etc.) and distally to the frame/assembly and overall “UMC” or “coupling solution”. This specific distal interface may further include features for controlling position/orientation of the frame/assembly, at the frame/assembly interface.
For example, in some embodiments, the arm/frame interface may comprise a ball joint wrist. In another example, the interface may include use of a gimbal wrist or an adjustable pitch and roll controlled wrist. These interfaces may be further employed with specific user interfaces and inputs, to assist with interacting with the various wrists, of which may include additional handles or knobs (as an unlimited example), to further enable positioning the UMC/coupling solution. For example, a gimbal wrist may benefit from allowing the frame/assembly to have 3 degrees of freedom (independent of the arm degrees of freedom), including pitch, roll and yaw adjustments.
Support arms, configured with arm wrists, further interfaced with frames/assemblies, may comprise features such as brakes, including cable or electronic actuated brakes, and quick releases, which may interact with one or more axis, individually, or in groupings. They may also include electronic lift systems and base supports. In some embodiments, these lift systems/base supports are co-located with robot arm bases, wherein said robot arm is equipped with the histotripsy therapy transducer configured to fit/work within the enclosed coupling solution. In other embodiments, the support arm is located on a separate cart. In some cases, the separate cart may comprise a fluidics system or user console. In other embodiments, it is interfaced to a bed/table, including but not limited to a rail, side surface, and/or bed/table base. In other examples/embodiments, it's interfaced to a floor-based structure/footing, capable of managing weight and tipping requirements.
Fluidics Systems, Control Systems and System Architectures
As a part of overall fluidics management, histotripsy systems including acoustic/patient coupling systems, may be configured to include an automated fluidics system, which primarily is responsible for providing a reservoir for preparation and use of coupling medium, where preparation may include the ability to degas, chill, monitor, adjust, dispense/fill, and retrieve/drain coupling medium to/from the frame/assembly. The fluidics system may include an emergency high flow rate system for rapid draining of the coupling medium from the UMC. In some embodiments, the fluidics system can be configured for a single use of the coupling medium, or alternatively, for re-use of the medium. In some embodiments, the fluidics system can implement positive air pressure or vacuum to carry out leak tests of the UMC and membrane prior to filling with a coupling medium. Vacuum assist can also be used for removal of air from the UMC during the filling process. The fluidics system can further include filters configured to prevent particulate contamination from reaching the UMC.
The fluidics system may be implemented in the form of a mobile fluidics cart. The cart may comprise an input tank, drain tank, degassing module, fill pump, drain pump, inert gas tank, air compressor, tubing/connectors/lines, electronic and manual controls systems and input devices, power supplies and one or more batteries. The cart in some cases may also comprise a system check vessel/reservoir for evaluating histotripsy system performance and related system diagnostics (configured to accommodate a required water volume and work-space for a therapy transducer).
It should be understood that any feature described herein with respect to one embodiment can be substituted for or combined with any feature described with respect to another embodiment.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This patent application is a continuation of U.S. application Ser. No. 18/497,856, filed Oct. 30, 2023, which claims priority to U.S. provisional patent application No. 63/381,401, titled “HISTOTRIPSY SYSTEMS AND METHODS” and filed on Oct. 28, 2022, which is herein incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3243497 | Kendall et al. | Mar 1966 | A |
| 3679021 | Goldberg et al. | Jul 1972 | A |
| 3693415 | Whittington | Sep 1972 | A |
| 3879699 | Pepper | Apr 1975 | A |
| 4016749 | Wachter | Apr 1977 | A |
| 4024501 | Herring et al. | May 1977 | A |
| 4051394 | Tieden | Sep 1977 | A |
| 4114457 | Thun | Sep 1978 | A |
| 4117446 | Alais | Sep 1978 | A |
| 4266747 | Souder, Jr. et al. | May 1981 | A |
| 4269174 | Adair | May 1981 | A |
| 4277367 | Madsen et al. | Jul 1981 | A |
| 4351038 | Alais | Sep 1982 | A |
| 4406153 | Ophir et al. | Sep 1983 | A |
| 4440025 | Hayakawa et al. | Apr 1984 | A |
| 4447031 | Souder, Jr. et al. | May 1984 | A |
| 4453408 | Clayman | Jun 1984 | A |
| 4483343 | Beyer et al. | Nov 1984 | A |
| 4483345 | Miwa | Nov 1984 | A |
| 4548374 | Thompson et al. | Oct 1985 | A |
| 4549533 | Cain et al. | Oct 1985 | A |
| 4550606 | Drost | Nov 1985 | A |
| 4551794 | Sandell | Nov 1985 | A |
| 4575330 | Hull | Mar 1986 | A |
| 4622972 | Giebeler, Jr. | Nov 1986 | A |
| 4625731 | Quedens et al. | Dec 1986 | A |
| 4641378 | McConnell et al. | Feb 1987 | A |
| 4669483 | Hepp et al. | Jun 1987 | A |
| 4689986 | Carson et al. | Sep 1987 | A |
| 4757820 | Itoh | Jul 1988 | A |
| 4791915 | Barsotti et al. | Dec 1988 | A |
| 4819621 | Ueberle et al. | Apr 1989 | A |
| 4829491 | Saugeon et al. | May 1989 | A |
| 4856107 | Dory | Aug 1989 | A |
| 4865042 | Umemura et al. | Sep 1989 | A |
| 4888746 | Wurster et al. | Dec 1989 | A |
| 4890267 | Rudolph | Dec 1989 | A |
| 4922917 | Dory | May 1990 | A |
| 4928672 | Grasser et al. | May 1990 | A |
| 4938217 | Lele | Jul 1990 | A |
| 4957099 | Hassler | Sep 1990 | A |
| 4973980 | Howkins et al. | Nov 1990 | A |
| 4984575 | Uchiyama et al. | Jan 1991 | A |
| 4991151 | Dory | Feb 1991 | A |
| 4995012 | Dory | Feb 1991 | A |
| RE33590 | Dory | May 1991 | E |
| 5014686 | Schafer | May 1991 | A |
| 5065751 | Wolf | Nov 1991 | A |
| 5078140 | Kwoh | Jan 1992 | A |
| 5080101 | Dory | Jan 1992 | A |
| 5080102 | Dory | Jan 1992 | A |
| 5091893 | Smith et al. | Feb 1992 | A |
| 5092336 | Fink | Mar 1992 | A |
| 5097709 | Masuzawa et al. | Mar 1992 | A |
| 5111822 | Dory | May 1992 | A |
| 5143073 | Dory | Sep 1992 | A |
| 5143074 | Dory | Sep 1992 | A |
| 5150711 | Dory | Sep 1992 | A |
| 5158070 | Dory | Oct 1992 | A |
| 5158071 | Umemura et al. | Oct 1992 | A |
| 5163421 | Bernstein et al. | Nov 1992 | A |
| 5165412 | Okazaki | Nov 1992 | A |
| 5174294 | Saito et al. | Dec 1992 | A |
| 5195509 | Rentschler et al. | Mar 1993 | A |
| 5209221 | Riedlinger | May 1993 | A |
| 5215680 | D'Arrigo | Jun 1993 | A |
| 5219401 | Cathignol et al. | Jun 1993 | A |
| 5222806 | Roberts | Jun 1993 | A |
| 5230340 | Rhyne | Jul 1993 | A |
| 5295484 | Marcus et al. | Mar 1994 | A |
| 5316000 | Chapelon et al. | May 1994 | A |
| 5354258 | Dory | Oct 1994 | A |
| 5380411 | Schlief | Jan 1995 | A |
| 5393296 | Rattner | Feb 1995 | A |
| 5409002 | Pell | Apr 1995 | A |
| 5431621 | Dory | Jul 1995 | A |
| 5435311 | Umemura et al. | Jul 1995 | A |
| 5443069 | Schaetzle | Aug 1995 | A |
| 5450305 | Boys et al. | Sep 1995 | A |
| 5469852 | Nakamura et al. | Nov 1995 | A |
| 5474071 | Chapelon et al. | Dec 1995 | A |
| 5474531 | Carter | Dec 1995 | A |
| 5490051 | Messana | Feb 1996 | A |
| 5492126 | Hennige et al. | Feb 1996 | A |
| 5501655 | Rolt et al. | Mar 1996 | A |
| 5520188 | Hennige et al. | May 1996 | A |
| 5523058 | Umemura et al. | Jun 1996 | A |
| 5524620 | Rosenschein | Jun 1996 | A |
| 5540909 | Schutt | Jul 1996 | A |
| 5542935 | Unger et al. | Aug 1996 | A |
| 5558092 | Unger et al. | Sep 1996 | A |
| 5563346 | Bartelt et al. | Oct 1996 | A |
| 5566675 | Li et al. | Oct 1996 | A |
| 5573497 | Chapelon | Nov 1996 | A |
| 5580575 | Unger et al. | Dec 1996 | A |
| 5582578 | Zhong et al. | Dec 1996 | A |
| 5590657 | Cain et al. | Jan 1997 | A |
| 5601526 | Chapelon et al. | Feb 1997 | A |
| 5617862 | Cole et al. | Apr 1997 | A |
| 5648098 | Porter | Jul 1997 | A |
| 5665054 | Dory | Sep 1997 | A |
| 5666954 | Chapelon et al. | Sep 1997 | A |
| 5676452 | Scholz | Oct 1997 | A |
| 5676692 | Sanghvi et al. | Oct 1997 | A |
| 5678554 | Hossack et al. | Oct 1997 | A |
| 5683064 | Copeland et al. | Nov 1997 | A |
| 5694936 | Fujimoto et al. | Dec 1997 | A |
| 5695460 | Siegel et al. | Dec 1997 | A |
| 5717657 | Ruffa | Feb 1998 | A |
| 5720287 | Chapelon et al. | Feb 1998 | A |
| 5724972 | Petrofsky | Mar 1998 | A |
| 5743863 | Chapelon | Apr 1998 | A |
| 5753929 | Bliss | May 1998 | A |
| 5759162 | Oppelt et al. | Jun 1998 | A |
| 5766138 | Rattner | Jun 1998 | A |
| 5769790 | Watkins et al. | Jun 1998 | A |
| 5797848 | Marian et al. | Aug 1998 | A |
| 5820623 | Ng | Oct 1998 | A |
| 5823962 | Schaetzle et al. | Oct 1998 | A |
| 5827204 | Grandia et al. | Oct 1998 | A |
| 5836896 | Rosenschein | Nov 1998 | A |
| 5849727 | Porter et al. | Dec 1998 | A |
| 5873902 | Sanghvi et al. | Feb 1999 | A |
| 5879314 | Peterson et al. | Mar 1999 | A |
| 5928169 | Schitzle et al. | Jul 1999 | A |
| 5932807 | Mallart | Aug 1999 | A |
| 5947904 | Hossack et al. | Sep 1999 | A |
| 6001069 | Tachibana et al. | Dec 1999 | A |
| 6007499 | Martin et al. | Dec 1999 | A |
| 6022309 | Celliers et al. | Feb 2000 | A |
| 6036667 | Manna et al. | Mar 2000 | A |
| 6088613 | Inger | Jul 2000 | A |
| 6093883 | Sanghvi et al. | Jul 2000 | A |
| 6113558 | Rosenschein et al. | Sep 2000 | A |
| 6126607 | Whitmore, III et al. | Oct 2000 | A |
| 6128958 | Cain | Oct 2000 | A |
| 6143018 | Beuthan et al. | Nov 2000 | A |
| 6165144 | Talish et al. | Dec 2000 | A |
| 6176842 | Tachibana et al. | Jan 2001 | B1 |
| 6296619 | Brisken et al. | Oct 2001 | B1 |
| 6308585 | Nilsson et al. | Oct 2001 | B1 |
| 6308710 | Silva | Oct 2001 | B1 |
| 6309355 | Cain et al. | Oct 2001 | B1 |
| 6318146 | Madsen et al. | Nov 2001 | B1 |
| 6321109 | Ben-Haim et al. | Nov 2001 | B2 |
| 6338566 | Verdier | Jan 2002 | B1 |
| 6344489 | Spears | Feb 2002 | B1 |
| 6391020 | Kurtz et al. | May 2002 | B1 |
| 6413216 | Cain et al. | Jul 2002 | B1 |
| 6419648 | Vitek et al. | Jul 2002 | B1 |
| 6470204 | Uzgiris et al. | Oct 2002 | B1 |
| 6488639 | Ribault et al. | Dec 2002 | B1 |
| 6490469 | Candy | Dec 2002 | B2 |
| 6500141 | Irion et al. | Dec 2002 | B1 |
| 6506154 | Ezion et al. | Jan 2003 | B1 |
| 6506171 | Vitek et al. | Jan 2003 | B1 |
| 6508774 | Acker et al. | Jan 2003 | B1 |
| 6511428 | Azuma et al. | Jan 2003 | B1 |
| 6511444 | Hynynen et al. | Jan 2003 | B2 |
| 6522142 | Freundlich | Feb 2003 | B1 |
| 6524251 | Rabiner et al. | Feb 2003 | B2 |
| 6536553 | Scanlon | Mar 2003 | B1 |
| 6543272 | Vitek | Apr 2003 | B1 |
| 6556750 | Constantino et al. | Apr 2003 | B2 |
| 6559644 | Froundlich et al. | May 2003 | B2 |
| 6576220 | Unge | Jun 2003 | B2 |
| 6599288 | Maguire et al. | Jul 2003 | B2 |
| 6607498 | Eshel | Aug 2003 | B2 |
| 6612988 | Maor et al. | Sep 2003 | B2 |
| 6613004 | Vitek et al. | Sep 2003 | B1 |
| 6613005 | Friedman et al. | Sep 2003 | B1 |
| 6626854 | Friedman et al. | Sep 2003 | B2 |
| 6626855 | Weng et al. | Sep 2003 | B1 |
| 6645162 | Friedman et al. | Nov 2003 | B2 |
| 6648839 | Manna et al. | Nov 2003 | B2 |
| 6666833 | Friedman et al. | Dec 2003 | B1 |
| 6685640 | Fry et al. | Feb 2004 | B1 |
| 6685657 | Jones | Feb 2004 | B2 |
| 6705994 | Vortman et al. | Mar 2004 | B2 |
| 6719449 | Laugharn, Jr. et al. | Apr 2004 | B1 |
| 6719694 | Weng et al. | Apr 2004 | B2 |
| 6735461 | Vitek et al. | May 2004 | B2 |
| 6736814 | Manna et al. | May 2004 | B2 |
| 6750463 | Riley | Jun 2004 | B1 |
| 6770031 | Hynynen et al. | Aug 2004 | B2 |
| 6775438 | Gaedke et al. | Aug 2004 | B1 |
| 6788977 | Fenn et al. | Sep 2004 | B2 |
| 6790180 | Vitek | Sep 2004 | B2 |
| 6820160 | Allman | Nov 2004 | B1 |
| 6852082 | Strickberger et al. | Feb 2005 | B2 |
| 6869439 | White et al. | Mar 2005 | B2 |
| 6890332 | Truckal et al. | May 2005 | B2 |
| 6929609 | Asafusa | Aug 2005 | B2 |
| 7004282 | Manna et al. | Feb 2006 | B2 |
| 7059168 | Hibi et al. | Jun 2006 | B2 |
| 7128711 | Medan et al. | Oct 2006 | B2 |
| 7128719 | Rosenberg | Oct 2006 | B2 |
| 7175596 | Vitek et al. | Feb 2007 | B2 |
| 7175599 | Hynynen et al. | Feb 2007 | B2 |
| 7196313 | Quinones | Mar 2007 | B2 |
| 7223239 | Schulze et al. | May 2007 | B2 |
| 7258674 | Cribbs et al. | Aug 2007 | B2 |
| 7273458 | Prausnitz et al. | Sep 2007 | B2 |
| 7273459 | Desilets et al. | Sep 2007 | B2 |
| 7300414 | Holland et al. | Nov 2007 | B1 |
| 7311679 | Desilets et al. | Dec 2007 | B2 |
| 7331951 | Eshel et al. | Feb 2008 | B2 |
| 7341569 | Soltani et al. | Mar 2008 | B2 |
| 7347855 | Eshel et al. | Mar 2008 | B2 |
| 7358226 | Dayton et al. | Apr 2008 | B2 |
| 7359640 | Onde et al. | Apr 2008 | B2 |
| 7367948 | O'Donnell et al. | May 2008 | B2 |
| 7374551 | Liang et al. | May 2008 | B2 |
| 7377900 | Vitek et al. | May 2008 | B2 |
| 7429249 | Winder et al. | Sep 2008 | B1 |
| 7431704 | Babaev | Oct 2008 | B2 |
| 7442168 | Novak et al. | Oct 2008 | B2 |
| 7462488 | Madsen et al. | Dec 2008 | B2 |
| 7559905 | Kagosaki et al. | Jul 2009 | B2 |
| 7656638 | Laakso et al. | Feb 2010 | B2 |
| 7695437 | Quistgaard et al. | Apr 2010 | B2 |
| 7714481 | Sakai | May 2010 | B2 |
| 7771359 | Adam | Aug 2010 | B2 |
| 7967763 | Deem et al. | Jun 2011 | B2 |
| 8057408 | Cain et al. | Nov 2011 | B2 |
| 8295912 | Gertner | Oct 2012 | B2 |
| 8333115 | Garvey et al. | Dec 2012 | B1 |
| 8337407 | Quistgaard et al. | Dec 2012 | B2 |
| 8342467 | Stachowski et al. | Jan 2013 | B2 |
| 8376970 | Babaev | Feb 2013 | B2 |
| 8539813 | Cain et al. | Sep 2013 | B2 |
| 8568339 | Rybyanets | Oct 2013 | B2 |
| 8636664 | Brannan | Jan 2014 | B2 |
| 8715187 | Landberg Davis et al. | May 2014 | B2 |
| 8845537 | Tanaka et al. | Sep 2014 | B2 |
| 8932239 | Sokka et al. | Jan 2015 | B2 |
| 9028434 | Tanaka | May 2015 | B2 |
| 9049783 | Teofilovic | Jun 2015 | B2 |
| 9061131 | Jahnke et al. | Jun 2015 | B2 |
| 9144694 | Cain | Sep 2015 | B2 |
| 9220476 | Coussios et al. | Dec 2015 | B2 |
| 9228730 | Inbody | Jan 2016 | B1 |
| 9302124 | Konofagou et al. | Apr 2016 | B2 |
| 9457201 | Hoelscher et al. | Oct 2016 | B2 |
| 9526923 | Jahnke et al. | Dec 2016 | B2 |
| 9636133 | Hall et al. | May 2017 | B2 |
| 9642634 | Cain et al. | May 2017 | B2 |
| 9763688 | Stulen et al. | Sep 2017 | B2 |
| 9901753 | Cain et al. | Feb 2018 | B2 |
| 9943708 | Roberts et al. | Apr 2018 | B2 |
| 10022107 | Thornton et al. | Jul 2018 | B2 |
| 10046179 | Oskar-Kohler | Aug 2018 | B2 |
| 10046181 | Barthe et al. | Aug 2018 | B2 |
| 10058352 | Carvell et al. | Aug 2018 | B2 |
| 10071266 | Cain | Sep 2018 | B2 |
| 10130828 | Vortman et al. | Nov 2018 | B2 |
| 10219815 | Maxwell et al. | Mar 2019 | B2 |
| 10293187 | Cannata et al. | May 2019 | B2 |
| 10751015 | Anderson et al. | Aug 2020 | B2 |
| 10751125 | Levy et al. | Aug 2020 | B2 |
| 10765892 | Vitek et al. | Sep 2020 | B1 |
| 10772646 | Lu et al. | Sep 2020 | B2 |
| 10780298 | Cain et al. | Sep 2020 | B2 |
| 10791991 | Burkett et al. | Oct 2020 | B2 |
| 10799209 | Lahti et al. | Oct 2020 | B2 |
| 10806421 | Keller | Oct 2020 | B2 |
| 10820813 | Alpert | Nov 2020 | B2 |
| 10847264 | Mansker et al. | Nov 2020 | B2 |
| 10849511 | Tochterman et al. | Dec 2020 | B2 |
| 10869603 | Millett et al. | Dec 2020 | B2 |
| 10869633 | Burkett | Dec 2020 | B2 |
| 10869648 | Hubbard et al. | Dec 2020 | B2 |
| 10874353 | Assif | Dec 2020 | B2 |
| 10874409 | Matsubara et al. | Dec 2020 | B2 |
| 10878586 | Brokman et al. | Dec 2020 | B2 |
| 10888232 | Anderson et al. | Jan 2021 | B2 |
| 10893808 | Dorando | Jan 2021 | B2 |
| 10900933 | Prus et al. | Jan 2021 | B2 |
| 10905394 | Stigall et al. | Feb 2021 | B2 |
| 10912463 | Davies et al. | Feb 2021 | B2 |
| 10925688 | Millett et al. | Feb 2021 | B2 |
| 10927003 | Millett et al. | Feb 2021 | B2 |
| 10932678 | Burkett | Mar 2021 | B2 |
| 10939826 | Glynn et al. | Mar 2021 | B2 |
| 10942022 | Johansson et al. | Mar 2021 | B2 |
| 10973419 | Corl | Apr 2021 | B2 |
| 10993618 | Mansker et al. | May 2021 | B2 |
| 10993628 | Tochterman | May 2021 | B2 |
| 10993694 | Meyer et al. | May 2021 | B2 |
| 11000185 | Stigall et al. | May 2021 | B2 |
| 11006840 | Stigall | May 2021 | B2 |
| 11013491 | Rice et al. | May 2021 | B2 |
| 11020087 | Hoffman | Jun 2021 | B2 |
| 11020089 | Corl | Jun 2021 | B2 |
| 11026591 | Burkett et al. | Jun 2021 | B2 |
| 11040140 | Unser et al. | Jun 2021 | B2 |
| 11058399 | Xu et al. | Jul 2021 | B2 |
| 11071522 | Hynynen et al. | Jul 2021 | B2 |
| 11103731 | Vortman et al. | Aug 2021 | B2 |
| 11112473 | Assif | Sep 2021 | B2 |
| 11119552 | Spencer et al. | Sep 2021 | B2 |
| 11120896 | Balignasay et al. | Sep 2021 | B2 |
| 11123019 | Merritt et al. | Sep 2021 | B2 |
| 11123575 | Vortman et al. | Sep 2021 | B2 |
| 11135454 | Xu et al. | Oct 2021 | B2 |
| 11141063 | Kemp et al. | Oct 2021 | B2 |
| 11141131 | Stigall et al. | Oct 2021 | B2 |
| 11160513 | Anderson et al. | Nov 2021 | B2 |
| 11205507 | Anderson et al. | Dec 2021 | B2 |
| 11219748 | Burkett et al. | Jan 2022 | B2 |
| 11224349 | Davies et al. | Jan 2022 | B2 |
| 11224403 | Corl | Jan 2022 | B2 |
| 11224407 | Wrolstad et al. | Jan 2022 | B2 |
| 11234649 | Matsubara et al. | Feb 2022 | B2 |
| 11246533 | Henderson et al. | Feb 2022 | B2 |
| 11246565 | Corl | Feb 2022 | B2 |
| 11253225 | Hancock et al. | Feb 2022 | B2 |
| 11260160 | Matsubara et al. | Mar 2022 | B2 |
| 11272845 | Cheline et al. | Mar 2022 | B2 |
| 11272904 | Vortman et al. | Mar 2022 | B2 |
| 11291866 | Levy et al. | Apr 2022 | B2 |
| 11298030 | Davies et al. | Apr 2022 | B2 |
| 11309071 | Anderson | Apr 2022 | B2 |
| 11311271 | Stigall et al. | Apr 2022 | B2 |
| 11324410 | Burkett | May 2022 | B2 |
| 11350906 | Castella et al. | Jun 2022 | B2 |
| 11350954 | De Cicco et al. | Jun 2022 | B2 |
| 11364042 | Maxwell et al. | Jun 2022 | B2 |
| 11369346 | De Cicco et al. | Jun 2022 | B2 |
| 11369994 | Greenberg et al. | Jun 2022 | B2 |
| 11395638 | Shin et al. | Jul 2022 | B2 |
| 11406334 | Merritt | Aug 2022 | B2 |
| 11406355 | Hoffman et al. | Aug 2022 | B2 |
| 11406498 | Stigall et al. | Aug 2022 | B2 |
| 11408987 | Vignon et al. | Aug 2022 | B2 |
| 11413017 | Stigall et al. | Aug 2022 | B2 |
| 11419580 | Stigall et al. | Aug 2022 | B2 |
| 11426140 | Sudol et al. | Aug 2022 | B2 |
| 11432795 | Merritt | Sep 2022 | B2 |
| 11432900 | Rakic et al. | Sep 2022 | B2 |
| 11446000 | Minas et al. | Sep 2022 | B2 |
| 11452496 | Minas et al. | Sep 2022 | B2 |
| 11452506 | Perez et al. | Sep 2022 | B2 |
| 11471215 | Stigall et al. | Oct 2022 | B2 |
| 11484294 | Hancock et al. | Nov 2022 | B2 |
| 11510632 | Begin et al. | Nov 2022 | B2 |
| 11517291 | Kantor et al. | Dec 2022 | B2 |
| 11520874 | Kennedy et al. | Dec 2022 | B2 |
| 11524183 | Garcia Gutierrez et al. | Dec 2022 | B1 |
| 11527001 | Brokman et al. | Dec 2022 | B2 |
| 11547389 | Shin et al. | Jan 2023 | B2 |
| 11553889 | Spencer et al. | Jan 2023 | B2 |
| 11554386 | Pernot et al. | Jan 2023 | B2 |
| 11559207 | Stigall et al. | Jan 2023 | B2 |
| 11567153 | Stormont et al. | Jan 2023 | B2 |
| 11576649 | Corl | Feb 2023 | B2 |
| 11576652 | De Cicco et al. | Feb 2023 | B2 |
| 11583193 | Groenland et al. | Feb 2023 | B2 |
| 11589835 | Stigall et al. | Feb 2023 | B2 |
| 11596351 | Nair | Mar 2023 | B2 |
| 11596384 | Nair et al. | Mar 2023 | B2 |
| 11596385 | Stigall et al. | Mar 2023 | B2 |
| 11596387 | Song | Mar 2023 | B2 |
| 11596389 | Nair | Mar 2023 | B2 |
| 11596469 | Nair | Mar 2023 | B2 |
| 11622746 | Minas et al. | Apr 2023 | B2 |
| 11638576 | Groenland et al. | May 2023 | B2 |
| 11647989 | Hope Simpson et al. | May 2023 | B2 |
| 11648424 | Cannata | May 2023 | B2 |
| 11653895 | Stigall et al. | May 2023 | B2 |
| 11660070 | Stigall et al. | May 2023 | B2 |
| 11666245 | Rajguru et al. | Jun 2023 | B2 |
| 11666307 | Unser | Jun 2023 | B2 |
| 11672433 | Park et al. | Jun 2023 | B2 |
| 11672552 | Pasquino et al. | Jun 2023 | B2 |
| 11672953 | May | Jun 2023 | B2 |
| 11684342 | Groenland et al. | Jun 2023 | B2 |
| 11684807 | Vortman et al. | Jun 2023 | B2 |
| 11701134 | Maxwell et al. | Jul 2023 | B2 |
| 11707207 | Stigall et al. | Jul 2023 | B2 |
| 11707254 | Di Tuillio et al. | Jul 2023 | B2 |
| 11733881 | Perez | Aug 2023 | B2 |
| 11737728 | Davies et al. | Aug 2023 | B2 |
| 11744527 | Scott et al. | Sep 2023 | B2 |
| 11744547 | Hynynen | Sep 2023 | B2 |
| 11759169 | Corl | Sep 2023 | B2 |
| 11759174 | Saroha et al. | Sep 2023 | B2 |
| 11766237 | Anderson | Sep 2023 | B2 |
| 11771370 | Hynynen | Oct 2023 | B2 |
| 11771405 | Rhodes | Oct 2023 | B2 |
| 11771869 | Cicco | Oct 2023 | B2 |
| 11779307 | Norris et al. | Oct 2023 | B2 |
| 11806167 | Burkett | Nov 2023 | B2 |
| 11813484 | Cannata et al. | Nov 2023 | B2 |
| 11813485 | Xu et al. | Nov 2023 | B2 |
| 11819712 | Cain et al. | Nov 2023 | B2 |
| 11854687 | Keller | Dec 2023 | B2 |
| 11857362 | Wrolstad et al. | Jan 2024 | B2 |
| 11857807 | Levy et al. | Jan 2024 | B2 |
| 11864918 | Burkett et al. | Jan 2024 | B2 |
| 11872412 | Vortman et al. | Jan 2024 | B2 |
| 11879973 | Prus et al. | Jan 2024 | B2 |
| 11883235 | Stigall et al. | Jan 2024 | B2 |
| 11890025 | Stigall et al. | Feb 2024 | B2 |
| 11890136 | Stigall et al. | Feb 2024 | B2 |
| 11890137 | Jenkins et al. | Feb 2024 | B2 |
| 11950954 | Hyun et al. | Apr 2024 | B2 |
| 11963822 | Wrolstad | Apr 2024 | B2 |
| 11986682 | Prus et al. | May 2024 | B2 |
| 11992366 | Stigall et al. | May 2024 | B2 |
| 12017013 | Sasamine et al. | Jun 2024 | B2 |
| 12035919 | Unser | Jul 2024 | B2 |
| 12036066 | De Cicco et al. | Jul 2024 | B2 |
| 12053194 | Goertz et al. | Aug 2024 | B2 |
| 12220259 | Burkett et al. | Feb 2025 | B2 |
| 12232907 | Chao et al. | Feb 2025 | B2 |
| 12246195 | Levy et al. | Mar 2025 | B2 |
| 20010039420 | Burbank et al. | Nov 2001 | A1 |
| 20010041163 | Sugita | Nov 2001 | A1 |
| 20020045890 | Celliers et al. | Apr 2002 | A1 |
| 20020078964 | Kovac et al. | Jun 2002 | A1 |
| 20020099356 | Unger et al. | Jul 2002 | A1 |
| 20020145091 | Talish et al. | Oct 2002 | A1 |
| 20030092982 | Eppstein | May 2003 | A1 |
| 20030112922 | Burdette et al. | Jun 2003 | A1 |
| 20030149352 | Liang et al. | Aug 2003 | A1 |
| 20030157025 | Unger et al. | Aug 2003 | A1 |
| 20030169591 | Cochran | Sep 2003 | A1 |
| 20030181833 | Faragalla et al. | Sep 2003 | A1 |
| 20030199857 | Eizenhofer | Oct 2003 | A1 |
| 20030221561 | Milo | Dec 2003 | A1 |
| 20030236539 | Rabiner et al. | Dec 2003 | A1 |
| 20040127815 | Marchitto et al. | Jul 2004 | A1 |
| 20040138563 | Moehring et al. | Jul 2004 | A1 |
| 20040162571 | Rabiner et al. | Aug 2004 | A1 |
| 20040164213 | Stephan | Aug 2004 | A1 |
| 20040236248 | Svedman | Nov 2004 | A1 |
| 20040243021 | Murphy et al. | Dec 2004 | A1 |
| 20040249509 | Rogers et al. | Dec 2004 | A1 |
| 20040260214 | Echt et al. | Dec 2004 | A1 |
| 20050011296 | Koseki | Jan 2005 | A1 |
| 20050020945 | Tosaya et al. | Jan 2005 | A1 |
| 20050038339 | Chauhan et al. | Feb 2005 | A1 |
| 20050038361 | Zhong et al. | Feb 2005 | A1 |
| 20050152561 | Spencer | Jul 2005 | A1 |
| 20050154314 | Quistgaard | Jul 2005 | A1 |
| 20050154431 | Quistgaard et al. | Jul 2005 | A1 |
| 20050203399 | Vaezy et al. | Sep 2005 | A1 |
| 20050215901 | Anderson et al. | Sep 2005 | A1 |
| 20050234438 | Mast et al. | Oct 2005 | A1 |
| 20050283098 | Conston et al. | Dec 2005 | A1 |
| 20060058678 | Vitek et al. | Mar 2006 | A1 |
| 20060060991 | Holsteyns et al. | Mar 2006 | A1 |
| 20060074303 | Chornenky et al. | Apr 2006 | A1 |
| 20060089636 | Christopherson et al. | Apr 2006 | A1 |
| 20060173321 | Kubota et al. | Aug 2006 | A1 |
| 20060173387 | Hansmann et al. | Aug 2006 | A1 |
| 20060184166 | Valle et al. | Aug 2006 | A1 |
| 20060206028 | Lee et al. | Sep 2006 | A1 |
| 20060229659 | Gifford et al. | Oct 2006 | A1 |
| 20060241466 | Ottoboni et al. | Oct 2006 | A1 |
| 20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
| 20060241533 | Geller | Oct 2006 | A1 |
| 20060264760 | Liu et al. | Nov 2006 | A1 |
| 20060293598 | Fraser | Dec 2006 | A1 |
| 20060293630 | Manna et al. | Dec 2006 | A1 |
| 20070010805 | Fedewa et al. | Jan 2007 | A1 |
| 20070016039 | Vortman et al. | Jan 2007 | A1 |
| 20070044562 | Sarr | Mar 2007 | A1 |
| 20070065420 | Johnson | Mar 2007 | A1 |
| 20070083120 | Cain et al. | Apr 2007 | A1 |
| 20070161902 | Dan | Jul 2007 | A1 |
| 20070167764 | Hynynen | Jul 2007 | A1 |
| 20070205785 | Nilsson | Sep 2007 | A1 |
| 20070219448 | Seip et al. | Sep 2007 | A1 |
| 20070239001 | Mehl et al. | Oct 2007 | A1 |
| 20080013593 | Kawabata | Jan 2008 | A1 |
| 20080033297 | Sliwa | Feb 2008 | A1 |
| 20080033417 | Nields et al. | Feb 2008 | A1 |
| 20080051656 | Vaezy et al. | Feb 2008 | A1 |
| 20080055003 | Unnikrishnan et al. | Mar 2008 | A1 |
| 20080082026 | Schmidt et al. | Apr 2008 | A1 |
| 20080091125 | Owen et al. | Apr 2008 | A1 |
| 20080126665 | Burr et al. | May 2008 | A1 |
| 20080154132 | Hall et al. | Jun 2008 | A1 |
| 20080167555 | Qian et al. | Jul 2008 | A1 |
| 20080177180 | Azhari et al. | Jul 2008 | A1 |
| 20080194965 | Sliwa et al. | Aug 2008 | A1 |
| 20080214964 | Chapelon et al. | Sep 2008 | A1 |
| 20080262345 | Fichtinger et al. | Oct 2008 | A1 |
| 20080262486 | Zvuloni et al. | Oct 2008 | A1 |
| 20080300485 | Liu et al. | Dec 2008 | A1 |
| 20080312561 | Chauhan | Dec 2008 | A1 |
| 20080319376 | Wilcox et al. | Dec 2008 | A1 |
| 20090012514 | Moonen et al. | Jan 2009 | A1 |
| 20090030339 | Cheng et al. | Jan 2009 | A1 |
| 20090036773 | Lau et al. | Feb 2009 | A1 |
| 20090112098 | Vaezy et al. | Apr 2009 | A1 |
| 20090198094 | Fenster et al. | Aug 2009 | A1 |
| 20090211587 | Lawrentschuk | Aug 2009 | A1 |
| 20090227874 | Suri et al. | Sep 2009 | A1 |
| 20090230822 | Kushculey et al. | Sep 2009 | A1 |
| 20090254008 | Shields, Jr. | Oct 2009 | A1 |
| 20090287083 | Kushculey et al. | Nov 2009 | A1 |
| 20090306502 | Lacoste | Dec 2009 | A1 |
| 20100011845 | Laugharn et al. | Jan 2010 | A1 |
| 20100042020 | Ben-Ezra | Feb 2010 | A1 |
| 20100056924 | Powers | Mar 2010 | A1 |
| 20100059264 | Hasegawa et al. | Mar 2010 | A1 |
| 20100069797 | Cain et al. | Mar 2010 | A1 |
| 20100125225 | Gelbart et al. | May 2010 | A1 |
| 20100152624 | Tanis et al. | Jun 2010 | A1 |
| 20100163694 | Fadler et al. | Jul 2010 | A1 |
| 20100204578 | Schmidt et al. | Aug 2010 | A1 |
| 20100261994 | Davalos et al. | Oct 2010 | A1 |
| 20100274136 | Cerofolini | Oct 2010 | A1 |
| 20100286519 | Lee et al. | Nov 2010 | A1 |
| 20100298744 | Altshuler et al. | Nov 2010 | A1 |
| 20100305432 | Duhay et al. | Dec 2010 | A1 |
| 20100317971 | Fan et al. | Dec 2010 | A1 |
| 20100318002 | Prus et al. | Dec 2010 | A1 |
| 20110072970 | Slobodzian et al. | Mar 2011 | A1 |
| 20110112400 | Emery et al. | May 2011 | A1 |
| 20110118600 | Gertner | May 2011 | A1 |
| 20110118602 | Weng et al. | May 2011 | A1 |
| 20110144490 | Davis et al. | Jun 2011 | A1 |
| 20110144545 | Fan et al. | Jun 2011 | A1 |
| 20110172529 | Gertner | Jul 2011 | A1 |
| 20110178444 | Slayton et al. | Jul 2011 | A1 |
| 20110245671 | Sato | Oct 2011 | A1 |
| 20110251528 | Canney et al. | Oct 2011 | A1 |
| 20110257524 | Gertner | Oct 2011 | A1 |
| 20110263967 | Bailey et al. | Oct 2011 | A1 |
| 20110270136 | Vitek et al. | Nov 2011 | A1 |
| 20110319927 | Nita | Dec 2011 | A1 |
| 20120029337 | Aoyagi | Feb 2012 | A1 |
| 20120029353 | Slayton et al. | Feb 2012 | A1 |
| 20120029393 | Lee | Feb 2012 | A1 |
| 20120059264 | Hope Simpson et al. | Mar 2012 | A1 |
| 20120059285 | Soltani et al. | Mar 2012 | A1 |
| 20120092724 | Pettis | Apr 2012 | A1 |
| 20120111339 | Barthe et al. | May 2012 | A1 |
| 20120130288 | Holland et al. | May 2012 | A1 |
| 20120136279 | Tanaka et al. | May 2012 | A1 |
| 20120158013 | Stefanchik et al. | Jun 2012 | A1 |
| 20120172720 | Asami et al. | Jul 2012 | A1 |
| 20120189998 | Kruecker et al. | Jul 2012 | A1 |
| 20120215157 | Berryman et al. | Aug 2012 | A1 |
| 20120232388 | Curra et al. | Sep 2012 | A1 |
| 20120259250 | Sapozhnikov et al. | Oct 2012 | A1 |
| 20120271167 | Holland et al. | Oct 2012 | A1 |
| 20120271223 | Khanna | Oct 2012 | A1 |
| 20120281902 | Oikawa et al. | Nov 2012 | A1 |
| 20130051178 | Rybyanets | Feb 2013 | A1 |
| 20130053691 | Kawabata et al. | Feb 2013 | A1 |
| 20130090579 | Cain et al. | Apr 2013 | A1 |
| 20130102932 | Cain et al. | Apr 2013 | A1 |
| 20130144165 | Ebbini et al. | Jun 2013 | A1 |
| 20130172739 | Paladini | Jul 2013 | A1 |
| 20130190623 | Bertolina et al. | Jul 2013 | A1 |
| 20130190661 | Wing et al. | Jul 2013 | A1 |
| 20130255426 | Kassow et al. | Oct 2013 | A1 |
| 20130303906 | Cain et al. | Nov 2013 | A1 |
| 20140030806 | Dudley et al. | Jan 2014 | A1 |
| 20140046181 | Benchimol et al. | Feb 2014 | A1 |
| 20140058293 | Hynynen et al. | Feb 2014 | A1 |
| 20140058294 | Gross et al. | Feb 2014 | A1 |
| 20140073995 | Teofilovic et al. | Mar 2014 | A1 |
| 20140074076 | Gertner | Mar 2014 | A1 |
| 20140088613 | Seo et al. | Mar 2014 | A1 |
| 20140100459 | Xu et al. | Apr 2014 | A1 |
| 20140112107 | Guo et al. | Apr 2014 | A1 |
| 20140128734 | Genstler et al. | May 2014 | A1 |
| 20140200489 | Behar et al. | Jul 2014 | A1 |
| 20140243664 | El-Sayed et al. | Aug 2014 | A1 |
| 20140316269 | Zhang et al. | Oct 2014 | A1 |
| 20140324034 | Assaf et al. | Oct 2014 | A1 |
| 20140330124 | Carol | Nov 2014 | A1 |
| 20140378832 | Sanghvi et al. | Dec 2014 | A1 |
| 20140378964 | Pearson | Dec 2014 | A1 |
| 20150011875 | Noordhoek et al. | Jan 2015 | A1 |
| 20150011916 | Cannata | Jan 2015 | A1 |
| 20150063668 | You et al. | Mar 2015 | A1 |
| 20150073261 | Kohler et al. | Mar 2015 | A1 |
| 20150080926 | Emery | Mar 2015 | A1 |
| 20150148659 | Vahala | May 2015 | A1 |
| 20150151141 | Arnal et al. | Jun 2015 | A1 |
| 20150190121 | Slayton et al. | Jul 2015 | A1 |
| 20150190659 | Kolher | Jul 2015 | A1 |
| 20150196239 | Meehan et al. | Jul 2015 | A1 |
| 20150224347 | Barthe et al. | Aug 2015 | A1 |
| 20150257779 | Sinelnikov et al. | Sep 2015 | A1 |
| 20150258352 | Lin et al. | Sep 2015 | A1 |
| 20150273246 | Darlington et al. | Oct 2015 | A1 |
| 20150297177 | Boctor et al. | Oct 2015 | A1 |
| 20160004933 | Hu et al. | Jan 2016 | A1 |
| 20160114194 | Gertner | Apr 2016 | A1 |
| 20160120572 | Lee | May 2016 | A1 |
| 20160135782 | Chen et al. | May 2016 | A1 |
| 20160151618 | Powers et al. | Jun 2016 | A1 |
| 20160184614 | Matula et al. | Jun 2016 | A1 |
| 20160206341 | Slayton | Jul 2016 | A1 |
| 20160206867 | Hossack et al. | Jul 2016 | A1 |
| 20160249859 | Babkin et al. | Sep 2016 | A1 |
| 20160287909 | Maxwell et al. | Oct 2016 | A1 |
| 20160303166 | Katz et al. | Oct 2016 | A1 |
| 20160331583 | Geringer | Nov 2016 | A1 |
| 20160331585 | Kim | Nov 2016 | A1 |
| 20160339273 | Al Mayiah | Nov 2016 | A1 |
| 20160345938 | Tanter et al. | Dec 2016 | A1 |
| 20160354087 | Noonan et al. | Dec 2016 | A1 |
| 20160361574 | Barthe et al. | Dec 2016 | A1 |
| 20170000376 | Partanen et al. | Jan 2017 | A1 |
| 20170049463 | Popovic et al. | Feb 2017 | A1 |
| 20170071515 | Chevillet et al. | Mar 2017 | A1 |
| 20170072227 | Khokhlova et al. | Mar 2017 | A1 |
| 20170072228 | Wang et al. | Mar 2017 | A1 |
| 20170100145 | Khoklova et al. | Apr 2017 | A1 |
| 20170120080 | Phillips et al. | May 2017 | A1 |
| 20170165046 | Johnson et al. | Jun 2017 | A1 |
| 20170183062 | Lee | Jul 2017 | A1 |
| 20170232277 | Hall et al. | Aug 2017 | A1 |
| 20170281983 | Marquet et al. | Oct 2017 | A1 |
| 20180000444 | Dayton et al. | Jan 2018 | A1 |
| 20180028841 | Konofagou et al. | Feb 2018 | A1 |
| 20180064412 | Messas et al. | Mar 2018 | A1 |
| 20180161086 | Davalos et al. | Jun 2018 | A1 |
| 20180169444 | Averkiou et al. | Jun 2018 | A1 |
| 20180206816 | Prus et al. | Jul 2018 | A1 |
| 20180236271 | Tanter et al. | Aug 2018 | A1 |
| 20180317884 | Chapelon et al. | Nov 2018 | A1 |
| 20190000422 | West et al. | Jan 2019 | A1 |
| 20190023804 | Onik et al. | Jan 2019 | A1 |
| 20190275353 | Cannata et al. | Sep 2019 | A1 |
| 20190282294 | Davalos et al. | Sep 2019 | A1 |
| 20190314045 | Cunitz et al. | Oct 2019 | A1 |
| 20190320904 | Mei | Oct 2019 | A1 |
| 20190323086 | Leuthardt et al. | Oct 2019 | A1 |
| 20190328500 | Cichon et al. | Oct 2019 | A1 |
| 20200010575 | Hode et al. | Jan 2020 | A1 |
| 20200055085 | Taffier | Feb 2020 | A1 |
| 20200078608 | Maxwell et al. | Mar 2020 | A1 |
| 20200107843 | Goertz et al. | Apr 2020 | A1 |
| 20200182989 | Freeman et al. | Jun 2020 | A1 |
| 20200194117 | Krieger et al. | Jun 2020 | A1 |
| 20200253550 | Nair | Aug 2020 | A1 |
| 20200254285 | Jang et al. | Aug 2020 | A1 |
| 20200260964 | Collins et al. | Aug 2020 | A1 |
| 20200282239 | Beder et al. | Sep 2020 | A1 |
| 20200305842 | Rosenzweig et al. | Oct 2020 | A1 |
| 20200323515 | Levy | Oct 2020 | A1 |
| 20200330039 | Burkett et al. | Oct 2020 | A1 |
| 20200330075 | O'Reilly et al. | Oct 2020 | A1 |
| 20200353293 | Khokhlova et al. | Nov 2020 | A1 |
| 20200367835 | Anderson | Nov 2020 | A1 |
| 20200375576 | Moulton | Dec 2020 | A1 |
| 20200405258 | Dayton et al. | Dec 2020 | A1 |
| 20200405259 | Merritt | Dec 2020 | A1 |
| 20210000541 | Levy et al. | Jan 2021 | A1 |
| 20210022703 | Nair | Jan 2021 | A1 |
| 20210022714 | Zagrodsky et al. | Jan 2021 | A1 |
| 20210100527 | Martin | Apr 2021 | A1 |
| 20210108866 | Lucht et al. | Apr 2021 | A1 |
| 20210161398 | Millett et al. | Jun 2021 | A1 |
| 20210169515 | Pahk et al. | Jun 2021 | A1 |
| 20210170204 | Vortman et al. | Jun 2021 | A1 |
| 20210170205 | Vortman et al. | Jun 2021 | A1 |
| 20210187331 | Zadicario et al. | Jun 2021 | A1 |
| 20210196295 | Goudot et al. | Jul 2021 | A1 |
| 20210220607 | Sasamine et al. | Jul 2021 | A1 |
| 20210330294 | Hynynen et al. | Oct 2021 | A1 |
| 20210353161 | Merritt et al. | Nov 2021 | A1 |
| 20210386451 | Escudero et al. | Dec 2021 | A1 |
| 20210401400 | Sheehan et al. | Dec 2021 | A1 |
| 20220008036 | Gulsen et al. | Jan 2022 | A1 |
| 20220022845 | Corl | Jan 2022 | A1 |
| 20220043143 | Prus et al. | Feb 2022 | A1 |
| 20220079563 | Kemp | Mar 2022 | A1 |
| 20220087640 | Minas et al. | Mar 2022 | A1 |
| 20220166462 | Deurenberg et al. | May 2022 | A1 |
| 20220167920 | Margolis | Jun 2022 | A1 |
| 20220168470 | Ricotti et al. | Jun 2022 | A1 |
| 20220196771 | Zur et al. | Jun 2022 | A1 |
| 20220203139 | Shapira | Jun 2022 | A1 |
| 20220219019 | Xu et al. | Jul 2022 | A1 |
| 20220233890 | Hynynen et al. | Jul 2022 | A1 |
| 20220240890 | Hancock et al. | Aug 2022 | A1 |
| 20220257329 | Stigall et al. | Aug 2022 | A1 |
| 20220280233 | Park et al. | Sep 2022 | A1 |
| 20220280367 | Diodato et al. | Sep 2022 | A1 |
| 20220296211 | Saroha et al. | Sep 2022 | A1 |
| 20220338750 | Allen et al. | Oct 2022 | A1 |
| 20220346756 | Chen | Nov 2022 | A1 |
| 20220370025 | Regensburger et al. | Nov 2022 | A1 |
| 20220386970 | Merritt | Dec 2022 | A1 |
| 20220395333 | Merritt et al. | Dec 2022 | A1 |
| 20220409171 | Sudol et al. | Dec 2022 | A1 |
| 20220409858 | Lin | Dec 2022 | A1 |
| 20230000466 | Levy et al. | Jan 2023 | A1 |
| 20230000469 | Prus et al. | Jan 2023 | A1 |
| 20230008714 | Rajguru et al. | Jan 2023 | A1 |
| 20230012365 | Alpert et al. | Jan 2023 | A1 |
| 20230024998 | Greenberg | Jan 2023 | A1 |
| 20230031859 | Davies et al. | Feb 2023 | A1 |
| 20230037603 | Pombo et al. | Feb 2023 | A1 |
| 20230038498 | Xu et al. | Feb 2023 | A1 |
| 20230038543 | Minas et al. | Feb 2023 | A1 |
| 20230042834 | Henderson et al. | Feb 2023 | A1 |
| 20230045488 | Rajguru et al. | Feb 2023 | A1 |
| 20230050732 | Hancock et al. | Feb 2023 | A1 |
| 20230061534 | Stopek | Mar 2023 | A1 |
| 20230073447 | Minas et al. | Mar 2023 | A1 |
| 20230100912 | Amar et al. | Mar 2023 | A1 |
| 20230112722 | Hoffman et al. | Apr 2023 | A1 |
| 20230114972 | Bigham et al. | Apr 2023 | A1 |
| 20230121688 | Begin et al. | Apr 2023 | A1 |
| 20230145064 | Vortman et al. | May 2023 | A1 |
| 20230181140 | Cohen et al. | Jun 2023 | A1 |
| 20230181156 | Cohen et al. | Jun 2023 | A1 |
| 20230190119 | Groenland et al. | Jun 2023 | A1 |
| 20230190215 | Nachtomy et al. | Jun 2023 | A1 |
| 20230190224 | Rajguru et al. | Jun 2023 | A1 |
| 20230190225 | Cohen et al. | Jun 2023 | A1 |
| 20230190226 | Rajguru et al. | Jun 2023 | A1 |
| 20230190227 | Cohen et al. | Jun 2023 | A1 |
| 20230190228 | Cohen et al. | Jun 2023 | A1 |
| 20230190229 | Cohen et al. | Jun 2023 | A1 |
| 20230190230 | Yang et al. | Jun 2023 | A1 |
| 20230191162 | Yau et al. | Jun 2023 | A1 |
| 20230196569 | Cohen et al. | Jun 2023 | A1 |
| 20230200899 | Nair | Jun 2023 | A1 |
| 20230201553 | Levy et al. | Jun 2023 | A1 |
| 20230218230 | Wu et al. | Jul 2023 | A1 |
| 20230218262 | Boutelle et al. | Jul 2023 | A1 |
| 20230218266 | Stigall et al. | Jul 2023 | A1 |
| 20230218269 | Alpert et al. | Jul 2023 | A1 |
| 20230218930 | Stopek et al. | Jul 2023 | A1 |
| 20230240615 | May et al. | Aug 2023 | A1 |
| 20230240647 | Minas et al. | Aug 2023 | A1 |
| 20230240792 | Rakic et al. | Aug 2023 | A1 |
| 20230255597 | O'Reilly et al. | Aug 2023 | A1 |
| 20230263507 | Groenland et al. | Aug 2023 | A1 |
| 20230270388 | Richardson et al. | Aug 2023 | A1 |
| 20230293148 | Stigall et al. | Sep 2023 | A1 |
| 20230293149 | Stigall et al. | Sep 2023 | A1 |
| 20230260601 | Abel et al. | Oct 2023 | A1 |
| 20230309859 | Sreedhar et al. | Oct 2023 | A1 |
| 20230310899 | Hall et al. | Oct 2023 | A1 |
| 20230310900 | Cannata et al. | Oct 2023 | A1 |
| 20230310901 | Cannata et al. | Oct 2023 | A1 |
| 20230320600 | Tochterman et al. | Oct 2023 | A1 |
| 20230321327 | Maxwell | Oct 2023 | A1 |
| 20230321398 | May | Oct 2023 | A1 |
| 20230329559 | Xu et al. | Oct 2023 | A1 |
| 20230333617 | Spencer et al. | Oct 2023 | A1 |
| 20230334659 | Marama et al. | Oct 2023 | A1 |
| 20230334677 | Sturm | Oct 2023 | A1 |
| 20230338010 | Sturm | Oct 2023 | A1 |
| 20230372025 | Van der Zaag et al. | Nov 2023 | A1 |
| 20230381544 | Penot et al. | Nov 2023 | A1 |
| 20230389891 | Cohen et al. | Dec 2023 | A1 |
| 20230398381 | Vitek et al. | Dec 2023 | A1 |
| 20240000422 | Cort | Jan 2024 | A1 |
| 20240000426 | Davies et al. | Jan 2024 | A1 |
| 20240001157 | Cannata et al. | Jan 2024 | A1 |
| 20240001158 | Cannata et al. | Jan 2024 | A1 |
| 20240023928 | Di Tullio et al. | Jan 2024 | A1 |
| 20240023930 | Anderson | Jan 2024 | A1 |
| 20240023941 | Rhodes | Jan 2024 | A1 |
| 20240065632 | Burkett | Feb 2024 | A1 |
| 20240138807 | Minas | May 2024 | A1 |
| 20240139553 | Miller et al. | May 2024 | A1 |
| 20240165666 | Hynynen et al. | May 2024 | A1 |
| 20240188929 | Minas et al. | Jun 2024 | A1 |
| 20240188931 | Ossmann et al. | Jun 2024 | A1 |
| 20240189267 | Bogott et al. | Jun 2024 | A1 |
| 20240189628 | Grumbir et al. | Jun 2024 | A1 |
| 20240225592 | May et al. | Jul 2024 | A1 |
| 20240245374 | Jenkins et al. | Jul 2024 | A1 |
| 20240245390 | Winkler Brown et al. | Jul 2024 | A1 |
| 20240245465 | Jenkins et al. | Jul 2024 | A1 |
| 20240269491 | Xu et al. | Aug 2024 | A1 |
| 20240285249 | May | Aug 2024 | A1 |
| 20250018227 | Son et al. | Jan 2025 | A1 |
| 20250040912 | Levy et al. | Feb 2025 | A1 |
| 20250041577 | Shapira et al. | Feb 2025 | A1 |
| 20250072872 | Nachtomy et al. | Mar 2025 | A1 |
| Number | Date | Country |
|---|---|---|
| 2017222925 | Nov 2021 | AU |
| 112018017326 | Dec 2022 | BR |
| 102023017634 | Jan 2025 | BR |
| 3073552 | Mar 2019 | CA |
| 3101381 | Nov 2019 | CA |
| 3055856 | Apr 2020 | CA |
| 3153080 | Apr 2021 | CA |
| 2910561 | Jul 2021 | CA |
| 2908740 | Oct 2021 | CA |
| 2980976 | Mar 2023 | CA |
| 2840014 | Aug 2023 | CA |
| 1669672 | Sep 2005 | CN |
| 1732031 | Feb 2006 | CN |
| 201197744 | Feb 2009 | CN |
| 102292123 | Dec 2011 | CN |
| 102481164 | May 2012 | CN |
| 102665585 | Sep 2012 | CN |
| 103537016 | Jan 2014 | CN |
| 103648361 | Mar 2014 | CN |
| 103812477 | May 2014 | CN |
| 104013444 | Sep 2014 | CN |
| 104135938 | Nov 2014 | CN |
| 104208822 | Dec 2014 | CN |
| 106999076 | Aug 2017 | CN |
| 109185113 | Jan 2019 | CN |
| 109219415 | Jan 2019 | CN |
| 109689160 | Apr 2019 | CN |
| 208725992 | Apr 2019 | CN |
| 111565642 | Aug 2020 | CN |
| 111655337 | Sep 2020 | CN |
| 111699022 | Sep 2020 | CN |
| 111712300 | Sep 2020 | CN |
| 111712301 | Sep 2020 | CN |
| 106999053 | Oct 2020 | CN |
| 107660137 | Oct 2020 | CN |
| 111757769 | Oct 2020 | CN |
| 112204412 | Jan 2021 | CN |
| 112236195 | Jan 2021 | CN |
| 106661535 | Mar 2021 | CN |
| 112533673 | Mar 2021 | CN |
| 112566694 | Mar 2021 | CN |
| 106999054 | May 2021 | CN |
| 106793997 | Jun 2021 | CN |
| 107530049 | Jun 2021 | CN |
| 112912011 | Jun 2021 | CN |
| 112912012 | Jun 2021 | CN |
| 112912013 | Jun 2021 | CN |
| 112969413 | Jun 2021 | CN |
| 112996445 | Jun 2021 | CN |
| 113167877 | Jul 2021 | CN |
| 113196080 | Jul 2021 | CN |
| 109196369 | Aug 2021 | CN |
| 109200484 | Aug 2021 | CN |
| 113316419 | Aug 2021 | CN |
| 113329788 | Aug 2021 | CN |
| 109640830 | Oct 2021 | CN |
| 113473917 | Oct 2021 | CN |
| 113507946 | Oct 2021 | CN |
| 113518588 | Oct 2021 | CN |
| 113705586 | Nov 2021 | CN |
| 110662575 | Dec 2021 | CN |
| 113905666 | Jan 2022 | CN |
| 114222536 | Mar 2022 | CN |
| 114366154 | Apr 2022 | CN |
| 114423362 | Apr 2022 | CN |
| 110248606 | Jun 2022 | CN |
| 115227992 | Oct 2022 | CN |
| 109843181 | Nov 2022 | CN |
| 115461000 | Dec 2022 | CN |
| 115515504 | Dec 2022 | CN |
| 109091768 | Mar 2023 | CN |
| 115779285 | Mar 2023 | CN |
| 115779287 | Mar 2023 | CN |
| 115813438 | Mar 2023 | CN |
| 111032157 | Apr 2023 | CN |
| 115916035 | Apr 2023 | CN |
| 110958858 | May 2023 | CN |
| 116172611 | May 2023 | CN |
| 111655337 | Jun 2023 | CN |
| 109416908 | Jul 2023 | CN |
| 116507295 | Jul 2023 | CN |
| 107529989 | Aug 2023 | CN |
| 111372522 | Aug 2023 | CN |
| 116617589 | Aug 2023 | CN |
| 112236195 | Sep 2023 | CN |
| 113615098 | Sep 2023 | CN |
| 114555247 | Sep 2023 | CN |
| 116744856 | Sep 2023 | CN |
| 116761554 | Sep 2023 | CN |
| 109416907 | Oct 2023 | CN |
| 117321444 | Dec 2023 | CN |
| 117500437 | Feb 2024 | CN |
| 117580499 | Feb 2024 | CN |
| 111212606 | Mar 2024 | CN |
| 113490459 | May 2024 | CN |
| 118042992 | May 2024 | CN |
| 118414127 | Jul 2024 | CN |
| 119367006 | Jan 2025 | CN |
| 112704620 | Feb 2025 | CN |
| 114287963 | Feb 2025 | CN |
| 3220751 | Dec 1983 | DE |
| 3544628 | Jun 1987 | DE |
| 3817094 | Nov 1989 | DE |
| 4012760 | May 1992 | DE |
| 0017382 | Oct 1980 | EP |
| 0320303 | Jun 1989 | EP |
| 0332871 | Sep 1989 | EP |
| 0384831 | Aug 1990 | EP |
| 0755653 | Jan 1997 | EP |
| 1374785 | Jan 2004 | EP |
| 1504713 | Feb 2005 | EP |
| 1566201 | Aug 2005 | EP |
| 2397188 | Dec 2011 | EP |
| 2934308 | Oct 2015 | EP |
| 2934309 | Oct 2015 | EP |
| 3097180 | Nov 2016 | EP |
| 2759003 | Aug 2020 | EP |
| 3558457 | Aug 2020 | EP |
| 3700629 | Sep 2020 | EP |
| 3218829 | Oct 2020 | EP |
| 3229688 | Oct 2020 | EP |
| 3723857 | Oct 2020 | EP |
| 2887989 | Feb 2021 | EP |
| 3777689 | Feb 2021 | EP |
| 2938253 | Mar 2021 | EP |
| 3076864 | Mar 2021 | EP |
| 2802276 | Apr 2021 | EP |
| 2809221 | Apr 2021 | EP |
| 3801761 | Apr 2021 | EP |
| 3801762 | Apr 2021 | EP |
| 3801763 | Apr 2021 | EP |
| 2967369 | May 2021 | EP |
| 2967488 | Jun 2021 | EP |
| 3184048 | Jun 2021 | EP |
| 2967370 | Sep 2021 | EP |
| 3482390 | Sep 2021 | EP |
| 3870067 | Sep 2021 | EP |
| 3870069 | Sep 2021 | EP |
| 3876843 | Sep 2021 | EP |
| 2931130 | Oct 2021 | EP |
| 2934304 | Oct 2021 | EP |
| 3887843 | Oct 2021 | EP |
| 3888534 | Oct 2021 | EP |
| 3895604 | Oct 2021 | EP |
| 3897391 | Oct 2021 | EP |
| 3229672 | Nov 2021 | EP |
| 3902603 | Nov 2021 | EP |
| 3903672 | Nov 2021 | EP |
| 2964096 | Dec 2021 | EP |
| 3930776 | Jan 2022 | EP |
| 3545829 | Mar 2022 | EP |
| 3959530 | Mar 2022 | EP |
| 3060129 | Apr 2022 | EP |
| 3986296 | Apr 2022 | EP |
| 3988167 | Apr 2022 | EP |
| 2914166 | May 2022 | EP |
| 3229674 | May 2022 | EP |
| 2779907 | Jun 2022 | EP |
| 3102098 | Jun 2022 | EP |
| 2965263 | Jul 2022 | EP |
| 2726152 | Aug 2022 | EP |
| 4041387 | Aug 2022 | EP |
| 4042936 | Aug 2022 | EP |
| 3298959 | Sep 2022 | EP |
| 2931131 | Nov 2022 | EP |
| 2938268 | Nov 2022 | EP |
| 3581103 | Nov 2022 | EP |
| 4087492 | Nov 2022 | EP |
| 4093470 | Nov 2022 | EP |
| 3091905 | Dec 2022 | EP |
| 4098203 | Dec 2022 | EP |
| 2950737 | Jan 2023 | EP |
| 3057496 | Jan 2023 | EP |
| 4114274 | Jan 2023 | EP |
| 4117534 | Jan 2023 | EP |
| 2869804 | Feb 2023 | EP |
| 2938265 | Feb 2023 | EP |
| 3024403 | Mar 2023 | EP |
| 4138672 | Mar 2023 | EP |
| 4151156 | Mar 2023 | EP |
| 2938271 | Apr 2023 | EP |
| 4161360 | Apr 2023 | EP |
| 4179995 | May 2023 | EP |
| 3171764 | Jun 2023 | EP |
| 4201342 | Jun 2023 | EP |
| 2931132 | Jul 2023 | EP |
| 3229695 | Jul 2023 | EP |
| 4209178 | Jul 2023 | EP |
| 4209179 | Jul 2023 | EP |
| 4226864 | Aug 2023 | EP |
| 4230121 | Aug 2023 | EP |
| 4230146 | Aug 2023 | EP |
| 4233972 | Aug 2023 | EP |
| 2866733 | Sep 2023 | EP |
| 3870069 | Sep 2023 | EP |
| 4247489 | Sep 2023 | EP |
| 3484371 | Oct 2023 | EP |
| 3658037 | Oct 2023 | EP |
| 3685874 | Oct 2023 | EP |
| 3870070 | Oct 2023 | EP |
| 2938255 | Nov 2023 | EP |
| 3229906 | Nov 2023 | EP |
| 3764914 | Nov 2023 | EP |
| 3903672 | Nov 2023 | EP |
| 4272654 | Nov 2023 | EP |
| 4275609 | Nov 2023 | EP |
| 3316804 | Dec 2023 | EP |
| 3519109 | Dec 2023 | EP |
| 3166479 | Jan 2024 | EP |
| 3537984 | Jan 2024 | EP |
| 3908195 | Feb 2024 | EP |
| 3182920 | Mar 2024 | EP |
| 3174643 | Apr 2024 | EP |
| 3814917 | Apr 2024 | EP |
| 4349283 | Apr 2024 | EP |
| 3681419 | May 2024 | EP |
| 4368118 | May 2024 | EP |
| 2804525 | Jun 2024 | EP |
| 4380667 | Jun 2024 | EP |
| 4385428 | Jun 2024 | EP |
| 4289415 | Jan 2025 | EP |
| 4406484 | Jan 2025 | EP |
| 3190958 | Feb 2025 | EP |
| 2774069 | Jul 2020 | ES |
| 2819552 | Apr 2021 | ES |
| 2829822 | Jun 2021 | ES |
| 2998435 | Feb 2025 | ES |
| 2099582 | Dec 1982 | GB |
| 1245715 | Jan 2021 | HK |
| 254768 | May 2021 | IL |
| 261285 | Feb 2022 | IL |
| 202117039853 | Dec 2021 | IN |
| 387413 | Jan 2022 | IN |
| 445766 | Aug 2023 | IN |
| 60-80779 | May 1985 | JP |
| 61-196718 | Aug 1986 | JP |
| 02-215451 | Aug 1990 | JP |
| H0422351 | Jan 1992 | JP |
| 06-197907 | Jul 1994 | JP |
| 07-504339 | May 1995 | JP |
| 08-84740 | Apr 1996 | JP |
| 06-304178 | May 1996 | JP |
| 08-131454 | May 1996 | JP |
| 09-55571 | Feb 1997 | JP |
| 10-512477 | Dec 1998 | JP |
| 2000300559 | Oct 2000 | JP |
| 2003510159 | Mar 2003 | JP |
| 2004505660 | Feb 2004 | JP |
| 2004249106 | Sep 2004 | JP |
| 2005167058 | Jun 2005 | JP |
| 2006511265 | Apr 2006 | JP |
| 2007144225 | Jun 2007 | JP |
| 2007520307 | Jul 2007 | JP |
| 2010019554 | Jan 2010 | JP |
| 2010029650 | Feb 2010 | JP |
| 2010204068 | Sep 2010 | JP |
| 2013538097 | Oct 2013 | JP |
| 2004512502 | Apr 2014 | JP |
| 2015519970 | Jul 2015 | JP |
| 2016508808 | Mar 2016 | JP |
| 2017506542 | Mar 2017 | JP |
| 2017506538 | Mar 2017 | JP |
| 2020525167 | Aug 2020 | JP |
| 2020525168 | Aug 2020 | JP |
| 2020525169 | Aug 2020 | JP |
| 6785554 | Oct 2020 | JP |
| 6789944 | Nov 2020 | JP |
| 2020534077 | Nov 2020 | JP |
| 2020195788 | Dec 2020 | JP |
| 2020535895 | Dec 2020 | JP |
| 6832958 | Feb 2021 | JP |
| 6835719 | Feb 2021 | JP |
| 6838057 | Mar 2021 | JP |
| 6849592 | Mar 2021 | JP |
| 2021510104 | Apr 2021 | JP |
| 6896719 | Jun 2021 | JP |
| 6934933 | Sep 2021 | JP |
| 6951560 | Oct 2021 | JP |
| 6979633 | Dec 2021 | JP |
| 6980696 | Dec 2021 | JP |
| 7012726 | Jan 2022 | JP |
| 2022500092 | Jan 2022 | JP |
| 2022500093 | Jan 2022 | JP |
| 2022501080 | Jan 2022 | JP |
| 2022504159 | Jan 2022 | JP |
| 2022509389 | Jan 2022 | JP |
| 2022509391 | Jan 2022 | JP |
| 2022509392 | Jan 2022 | JP |
| 2022509393 | Jan 2022 | JP |
| 2022509395 | Jan 2022 | JP |
| 2022509401 | Jan 2022 | JP |
| 2022509453 | Jan 2022 | JP |
| 2022510217 | Jan 2022 | JP |
| 7019679 | Feb 2022 | JP |
| 7026118 | Feb 2022 | JP |
| 2022514272 | Feb 2022 | JP |
| 2022515488 | Feb 2022 | JP |
| 2022516078 | Feb 2022 | JP |
| 7053500 | Apr 2022 | JP |
| 2022526104 | May 2022 | JP |
| 2022527043 | May 2022 | JP |
| 2022095785 | Jun 2022 | JP |
| 7171645 | Nov 2022 | JP |
| 7171663 | Nov 2022 | JP |
| 7175640 | Nov 2022 | JP |
| 2022546288 | Nov 2022 | JP |
| 7187715 | Dec 2022 | JP |
| 2022551875 | Dec 2022 | JP |
| 2022552229 | Dec 2022 | JP |
| 7201819 | Jan 2023 | JP |
| 7232204 | Mar 2023 | JP |
| 7239466 | Mar 2023 | JP |
| 7265525 | Apr 2023 | JP |
| 2023071859 | May 2023 | JP |
| 7292448 | Jun 2023 | JP |
| 7299992 | Jun 2023 | JP |
| 2023085350 | Jun 2023 | JP |
| 7302936 | Jul 2023 | JP |
| 7304344 | Jul 2023 | JP |
| 7321162 | Aug 2023 | JP |
| 7325430 | Aug 2023 | JP |
| 7335367 | Aug 2023 | JP |
| 2023116673 | Aug 2023 | JP |
| 7340594 | Sep 2023 | JP |
| 7346293 | Sep 2023 | JP |
| 7351972 | Sep 2023 | JP |
| 7352561 | Sep 2023 | JP |
| 2023123676 | Sep 2023 | JP |
| 2023134811 | Sep 2023 | JP |
| 7358391 | Oct 2023 | JP |
| 7359765 | Oct 2023 | JP |
| 7370386 | Oct 2023 | JP |
| 2023162327 | Nov 2023 | JP |
| 2024010135 | Jan 2024 | JP |
| 2024020483 | Feb 2024 | JP |
| 7479288 | May 2024 | JP |
| 7479351 | May 2024 | JP |
| 7485383 | May 2024 | JP |
| 7530561 | Aug 2024 | JP |
| 7542708 | Aug 2024 | JP |
| 7612816 | Jan 2025 | JP |
| 2025013082 | Jan 2025 | JP |
| 7641600 | Mar 2025 | JP |
| 7643694 | Mar 2025 | JP |
| 2025031814 | Mar 2025 | JP |
| 102574559 | Sep 2023 | KR |
| 102764982 | Feb 2025 | KR |
| 20250019597 | Feb 2025 | KR |
| WO9406355 | Mar 1994 | WO |
| WO0232506 | Apr 2002 | WO |
| WO2005018469 | Mar 2005 | WO |
| WO2008051484 | May 2008 | WO |
| WO2011040054 | Jul 2011 | WO |
| WO2011092683 | Aug 2011 | WO |
| WO2011154654 | Dec 2011 | WO |
| WO2014008594 | Jan 2014 | WO |
| WO2014071386 | May 2014 | WO |
| WO2015000953 | Jan 2015 | WO |
| WO2015031532 | Mar 2015 | WO |
| WO2015153909 | Oct 2015 | WO |
| WO2018149671 | Aug 2018 | WO |
| WO2019081329 | May 2019 | WO |
| WO2019122941 | Jun 2019 | WO |
| WO2020074615 | Apr 2020 | WO |
| WO2020087049 | Apr 2020 | WO |
| WO2020112688 | Jun 2020 | WO |
| WO2020217098 | Oct 2020 | WO |
| WO2020237382 | Dec 2020 | WO |
| WO2020245660 | Dec 2020 | WO |
| WO2021014221 | Jan 2021 | WO |
| WO2021032887 | Feb 2021 | WO |
| WO2021069216 | Apr 2021 | WO |
| WO2021069971 | Apr 2021 | WO |
| WO2021089810 | May 2021 | WO |
| WO2021105358 | Jun 2021 | WO |
| WO2021115958 | Jun 2021 | WO |
| WO2021116763 | Jun 2021 | WO |
| WO2021122253 | Jun 2021 | WO |
| WO2021123905 | Jun 2021 | WO |
| WO2021123906 | Jun 2021 | WO |
| WO2021140042 | Jul 2021 | WO |
| WO2021142090 | Jul 2021 | WO |
| WO2021170510 | Sep 2021 | WO |
| WO2021175626 | Sep 2021 | WO |
| WO2021176275 | Sep 2021 | WO |
| WO2021178961 | Sep 2021 | WO |
| WO2021180501 | Sep 2021 | WO |
| WO2021180550 | Sep 2021 | WO |
| WO2021213927 | Oct 2021 | WO |
| WO2021249936 | Dec 2021 | WO |
| WO2021258007 | Dec 2021 | WO |
| WO2022013266 | Jan 2022 | WO |
| WO2022040493 | Feb 2022 | WO |
| WO2022047193 | Mar 2022 | WO |
| WO2022056394 | Mar 2022 | WO |
| WO2022069254 | Apr 2022 | WO |
| WO2022069303 | Apr 2022 | WO |
| WO2022069327 | Apr 2022 | WO |
| WO2022078744 | Apr 2022 | WO |
| WO2022097138 | May 2022 | WO |
| WO2022106891 | May 2022 | WO |
| WO2022152724 | Jul 2022 | WO |
| WO2022152827 | Jul 2022 | WO |
| WO2022152828 | Jul 2022 | WO |
| WO2022228922 | Nov 2022 | WO |
| WO2022238058 | Nov 2022 | WO |
| WO2022238092 | Nov 2022 | WO |
| WO2022238229 | Nov 2022 | WO |
| WO2022238274 | Nov 2022 | WO |
| WO2022238276 | Nov 2022 | WO |
| WO2022238392 | Nov 2022 | WO |
| WO2022247242 | Dec 2022 | WO |
| WO2022258561 | Dec 2022 | WO |
| WO2022260746 | Dec 2022 | WO |
| WO2022260747 | Dec 2022 | WO |
| WO2023274899 | Jan 2023 | WO |
| WO2023275617 | Jan 2023 | WO |
| WO2023275771 | Jan 2023 | WO |
| WO2023012516 | Feb 2023 | WO |
| WO2023036742 | Mar 2023 | WO |
| WO2023052278 | Apr 2023 | WO |
| WO2023084307 | May 2023 | WO |
| WO2023104599 | Jun 2023 | WO |
| WO2023104841 | Jun 2023 | WO |
| WO2023110555 | Jun 2023 | WO |
| WO2023110556 | Jun 2023 | WO |
| WO2023110594 | Jun 2023 | WO |
| WO2023110607 | Jun 2023 | WO |
| WO2023117721 | Jun 2023 | WO |
| WO2023117821 | Jun 2023 | WO |
| WO2023117822 | Jun 2023 | WO |
| WO2023118080 | Jun 2023 | WO |
| WO2023105288 | Jun 2023 | WO |
| WO2023105290 | Jun 2023 | WO |
| WO2023131566 | Jul 2023 | WO |
| WO2023131574 | Jul 2023 | WO |
| WO2023135024 | Jul 2023 | WO |
| WO2023141653 | Jul 2023 | WO |
| WO2023152639 | Aug 2023 | WO |
| WO2023169967 | Sep 2023 | WO |
| WO2023180811 | Sep 2023 | WO |
| WO2023218428 | Nov 2023 | WO |
| WO2023230053 | Nov 2023 | WO |
| WO2023230054 | Nov 2023 | WO |
| WO2024009143 | Jan 2024 | WO |
| WO2024016088 | Jan 2024 | WO |
| WO2024040185 | Feb 2024 | WO |
| WO2024047580 | Mar 2024 | WO |
| WO2024092272 | May 2024 | WO |
| WO2024120659 | Jun 2024 | WO |
| WO2024125872 | Jun 2024 | WO |
| WO2024130252 | Jun 2024 | WO |
| WO2024144897 | Jul 2024 | WO |
| Entry |
|---|
| Cain et al.; U.S. Appl. No. 18/485,904 entitled “Histotripsy using very short ultrasound pulses,” filed Oct. 12, 2023. |
| Xu et al.; U.S. Appl. No. 18/555,683 entitled “Design and fabrication of therapeutic ultrasound transducer with arbitrarily shaped, densely packing, removable modular elements,” filed Oct. 16, 2023. |
| Akiyama et al.; Elliptically curved acoustic lens for emitting strongly focused finite-amplitude beams: Application of the spheroidal beam equation model to the theoretical prediction; Acoustical Science and Technology, vol. 26, pp. 279-284, May 2005. |
| Appel et al.; Stereoscopic highspeed recording of bubble filaments; Ultrasonics Sonochemistry; vol. 11(1); pp. 39-42; Jan. 2004. |
| Arani et al.; Transurethral prostate magnetic resonance elestography; prospective imaging requirements; Magn. Reson. Med.; 65(2); pp. 340-349; Feb. 2011. |
| Aschoff et al.; How does alteration of hepatic blood flow affect liver perfusion and radiofrequency-induced thermal lesion size in rabbit liver?; J Magn Reson Imaging; 13(1); pp. 57-63; Jan. 2001. |
| Atchley et al.; Thresholds for cavitation produced in water by pulsed ultrasound; Ultrasonics.; vol. 26(5); pp. 280-285; Sep. 1988. |
| Avago Technologies; ACNV2601 High Insulation Voltage 10 MBd Digital Opotcoupler. Avago Technologies Data Sheet; pp. 1-11; Jul. 29, 2010. |
| Avago Technologies; Avago's ACNV2601 optocoupler is an optically coupled logic gate; Data Sheet; 2 pages; Jul. 29, 2010. |
| AVTECH; AVR-8 Data sheet; May 23, 2004; 3 pages; retrieved from the internet (http//www.avtechpulse.com). |
| Bak; Rapid protytyping or rapid production? 3D printing processes move industry towards the latter; Assembly Automation; 23(4); pp. 340-345; Dec. 1, 2003. |
| Billson et al.; Rapid prototyping technologies for ultrasonic beam focussing in NDE; IEEE International Ultrasonic Symposium Proceedings; pp. 2472-2474; Oct. 2011. |
| Bjoerk et al.; Cool/MOS CP—How to make most beneficial use of the generation of super junction technology devices. Infineon Technologies AG. [retrieved Feb. 4, 2014] from the internet (http://www.infineon.com/dgdl/Infineon+-+Application+Note+-+PowerMOSFETs+-+600V+CoolMOS%E284%A2+-+CP+Most+beneficial+use+of+superjunction+technologie+devices.pdf?folderid=db3a304412b407950112b408e8c90004&fileId=db3a304412b407950112b40ac9a40688>pages1, 4, 14; Feb. 2007. |
| Bland et al.; Surgical Oncology; McGraw Hill; Chap. 5 (Cavitron Ultrasonic Aspirator); pp. 461-462; Jan. 29, 2001. |
| Burdin et al.; Implementation of the laser diffraction technique for cavitation bubble investigations; Particle & Particle Systems Characterization; vol. 19; pp. 73-83; May 2002. |
| Cain, Charles A.; Histotripsy: controlled mechanical sub-division of soft tissues by high intensity pulsed ultrasound (conference presentation); American Institute of Physics (AIP) Therapeutic Ultrasound: 5th International Symposium on Therapeutic Ultrasound; 44 pgs.; Oct. 27-29, 2005. |
| Canney et al.; Shock-Induced Heating and Millisecond Boiling in Gels and Tissue Due to High Intensity Focused Ultrasound; Ultrasound in Medicine & Biology, vol. 36, pp. 250-267; Feb. 2010 (author manuscript). |
| Chan et al.; An image-guided high intensity focused ultrasound device for uterine fibroids treatment; Medical Physics, vol. 29, pp. 2611-2620, Nov. 2002. |
| Clasen et al.; MR-guided radiofrequency ablation of hepatocellular carcinoma: Long-term effectiveness; J Vase Interv Radiol; 22(6); pp. 762-770; Jun. 2011. |
| Clement et al.; A hemisphere array for non-invasive ultrasound brain therapy and surgery; Physics in Medicine and Biology, vol. 45, p. 3707-3719, Dec. 2000. |
| Cline et al.; Magnetic resonance-guided thermal surgery; Magnetic Resonance in Medicine; 30(1); pp. 98-106; Jul. 1993. |
| Curiel et al.; Elastography for the follow-up of high-intensity focused ultrasound prostate cancer treatment: Initial comparison with MRI; Ultrasound Med. Biol; 31(11); pp. 1461-1468; Nov. 2005. |
| Desilets et al.; The Design of Efficient Broad-Band Piezoelectric Transducers; Sonics and Ultrasonics, IEEE Transactions on, vol. 25, pp. 115-125, May 1978. |
| Dovedi et al.; Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-LI Blockade; Cancer Research; 74(19); pp. 5458-5468; Oct. 1, 2014. |
| Emelianov et al.; Triplex ultrasound: Elasticity imaging to age deep venous thrombosis; Ultrasound Med Biol; 28(6); pp. 757-767; Jun. 2002. |
| Giannatsis et al.; Additive fabrication technologies applied to medicine and health care: a review; The International Journal of Advanced Manufacturing Technology; 40(1-2); pp. 116-127; Jan. 2009. |
| Gudra et al.; Influence of acoustic impedance of multilayer acoustic systems on the transfer function of ultrasonic airborne transducers; Ultrasonics, vol. 40, pp. 457-463, May 2002. |
| Hall et al.; A Low Cost Compact 512 Channel Therapeutic Ultrasound System For Transcutaneous Ultrasound Surgery; AIP Conference Proceedings, Boston, MA; vol. 829, pp. 445-449, Oct. 27-29, 2005. |
| Hall et al.; Acoustic Access to the Prostate for Extracorporeal Ultrasound Ablation; Journal of Endourology, vol. 24, pp. 1875-1881, Nov. 2010. |
| Hall et al.; Histotripsy of the prostate: dose effects in a chronic canine model; Urology; 74(4); pp. 932-937; Oct. 2009 (author manuscript). |
| Hall et al.; Imaging feedback of tissue liquefaction (histotripsy) in ultrasound surgery; IEEE Ultrasonic Symposium, Sep. 18-21, 2005, pp. 1732-1734. |
| Haller et al.; Determination of acoustic cavitation probabilities and thresholds using a single focusing transducer to induce and detect acoustic cavitation events: I. Method and terminology; Ultrasound in Medicine & Biology; 44(2); pp. 377-396; Feb. 1, 2018. |
| Hartmann; Ultrasonic properties of poly(4-methyl pentene-1), Journal of Applied Physics, vol. 51, pp. 310-314, Jan. 1980. |
| Hobarth et al.; Color flow doppler sonography for extracorporal shock wave lithotripsy; Journal of Urology; 150(6); pp. 1768-1770; Dec. 1, 1993. |
| Holland et al.; Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment; J. Acoust. Soc. Am.; vol. 88(5); pp. 2059-2069; Nov. 1990. |
| Huber et al.; Influence of shock wave pressure amplitude and pulse repetition frequency on the lifespan, size and number of transient cavities in the field of an electromagnetic lithotripter; Physics in Medicine and Biology; vol. 43(10); pp. 3113-3128; Oct. 1998. |
| Hynynen et al.; Tissue thermometry during ultrasound exposure; European Urology; 23(Suppl 1); pp. 12-16; (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue) 1993. |
| Kallel et al.; The feasibility of elastographic visualization of HIFU-induced thermal lesions in soft tissues: Image-guided high-intensity focused ultrasound; Ultrasound Med. Biol; 25(4); pp. 641-647; May 1999. |
| Khokhlova et al.; Controlled tissue emulsification produced by high intensity focused ultrasound shock waves and millisecond boiling; J. Acoust. Soc. Am.; 130(5), pt. 2; pp. 3498-3510; Nov. 2011. |
| Kim et al.; Dependence of particle volume fraction on sound velocity and attenuation of EPDM composites; Ultrasonics, vol. 46, pp. 177-183, Feb. 2007. |
| Kim et al.; Development of a wearable robotic positioning system for noninvasive transcranial focused ultrasound stimulation. IEEE/ASME Transactions on Mechatronics; 21(5); pp. 2284-2293; Jun. 13, 2016. |
| Konofagou; Quo vadis elasticity imaging?; Ultrasonics; 42(1-9); pp. 331-336; Apr. 2004. |
| Krimholtz et al.; New equivalent circuits for elementary piezoelectric transducers; Electronics Letters, vol. 6, pp. 398-399, Jun. 1970. |
| Kruse et al.; Tissue characterization using magnetic resonance elastography: Preliminary results; Phys. Med. Biol; 45(6); pp. 1579-1590; Jun. 2000. |
| Lake et al.; Histotripsy: minimally invasive technology for prostatic tissue ablation in an in vivo canine model; Urology; 72(3); pp. 682-686; Sep. 2008. |
| Lauterborn et al.; Cavitation bubble dynamics studied by high speed photography and holography: part one; Ultrasonics; vol. 23; pp. 260-268; Nov. 1985. |
| Lensing et al.; Deep-vein thrombosis; The Lancet, vol. 353, pp. 479-485, Feb. 6, 1999. |
| Lin et al.; Dual-beam histotripsy: a low-frequency pump enabling a high-frequency probe for precise lesion formation; IEEE Trans. Ultrason. Ferroelectr. Control; 61(2); pp. 325-340; Feb. 2014; (Author Manuscript; 29 pages). |
| Liu et al.; Real-time 2-D temperature imaging using ultrasound; IEEE Trans Biomed Eng; 57(1); pp. 12-16; Jan. 2010 (author manuscript, 16 pgs.). |
| Liu et al.; Viscoelastic property measurement in thin tissue constructs using ultrasound; IEEE Trans Ultrason Ferroelectr Freq Control; 55(2); pp. 368-383; Feb. 2008 (author manuscript, 37 pgs). |
| Macoskey; Acoustic methods for histotripsy feedback; (Dissertation); Biomedical Engineering and Science Computing; University of Michigan 2019; 207 pages; retrived from the internet (https://deepblue.lib.umich.edu/handle/2027.42/149988) on Feb. 2022. |
| Manes et al.; Design of a Simplified Delay System for Ultrasound Phased Array Imaging; Sonics and Ultrasonics, IEEE Transactions on, vol. 30, pp. 350-354, Nov. 1983. |
| Maréchal et al.; Effect of Radial Displacement of Lens on Response of Focused Ultrasonic Transducer; Japanese Journal of Applied Physics, vol. 46, p. 3077-3085; May 15, 2007. |
| Maréchal et al.; Lens-focused transducer modeling using an extended KLM model; Ultrasonics, vol. 46, pp. 155-167, May 2007. |
| Martin et al.; Water-cooled, high-intensity ultrasound surgical applicators with frequency tracking; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 50, pp. 1305-1317, Oct. 2003. |
| Maxwell et al.; Cavitation clouds created by shock scattering from bubbles during histotripsy; J. Acoust. Soc. Am.; 130(4); pp. 1888-1898; Oct. 2011. |
| Maxwell et al.; Noninvasive Thrombolysis Using Pulsed Ultrasound Cavitation Therapy—Histotripsy; Ultrasound in Medicine & Biology, vol. 35, pp. 1982-1994, Dec. 2009 (author manuscript). |
| Maxwell; Noninvasive thrombolysis using histotripsy pulsed ultrasound cavitation therapy; PhD Dissertation. University of Michigan, Ann Arbor, Michigan. Jun. 2012. |
| Maxwell et al.; In-vivo study of non-invasive thrombolysis by histotripsy in a porcine model; IEEE international Ultrasonics Symposium; IEEE; p. 220-223; Sep. 20, 2009. |
| Maxwell et al.; The role of compressional pressure in the formation of dense bubble clouds in histotripsy, 2009 IEEE International Ultrasonics Symposium; pp. 81-84, Sep. 20, 2009. |
| Miller et al.; A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective; Ultrasound in Medicine and Biology; vol. 22; pp. 1131-1154; (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue) 1996. |
| Miller et al.; Investigation of the mechanism of ARFI-based color doppler feedback of histotripsy tissue fractionation; Ultrasonic Symposium (IUS); 2013 IEEE International; 4 pages; Jul. 21-25, 2013. |
| Miller et al.; Real-time elastography-based monitoring of histotripsy tissue fractionation using color doppler; Ultrasonics Symposium (IUS); 2012 IEEE International; 8 pages; Oct. 7-10, 2012. |
| Nightingale et al.; Analysis of contrast in images generated with transient acoustic radiation force; Ultrasound Med Biol; 32(1); pp. 61-72; Jan. 2006. |
| Ohl et al.; Bubble dynamics, shock waves and sonoluminescence; Phil. Trans. R. Soc. Lond. A; vol. 357; pp. 269-294; (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue) 1999. |
| Okada et al.; A case of hepatocellular carcinoma treated by MR-guided focused ultrasound ablation with respiratory gating; Magn Reson Med Sci; 5(3); pp. 167-171; Oct. 2006. |
| Palmeri et al.; Acoustic radiation force-based elasticity imaging methods; Interface Focus; 1; pp. 553-564; Aug. 2011. |
| Parsons et al.; Cost-effective assembly of a basic fiber-optic hydrophone for measurement of high-amplitude therapeutic ultrasound fields; The Journal of the Acoustical Society of America, vol. 119, pp. 1432-1440, Mar. 2006. |
| Parsons et al.; Pulsed cavitational ultrasound therapy for controlled tissue homogenization; Ultrasound in Med. & Biol.; vol. 32(1); pp. 115-129; Jan. 2006. |
| Pishchalnikov et al.; Cavitation Bubble Cluster Activity in the Breakage of Kidney Stones by Lithotripter Shock Waves; J Endourol.; 17(7): 435-446; Sep. 2003. |
| Porter et al.; Reduction in left ventricular cavitary attenuation and improvement in posterior myocardial contrast . . . ; J Am Soc Echocardiography; pp. 437-441; Jul.-Aug. 1996. |
| Qu et al.; Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy; Journal for immunotherapy of cancer; 8(1); Jan. 15, 2020. |
| Roberts et al.; Pulsed cavitational ultrasound: a noninvasive technology for controlled tissue ablation (histotripsy) in the rabbit kidney; Journal of Urology; vol. 175(2); pp. 734-738; Feb. 2006. |
| Rosenschein et al.; Ultrasound Imaging-Guided Noninvasive Ultrasound Thrombolysis: Preclinical Results; Circulation; vol. 102; pp. 238-245, Jul. 11, 2000. |
| Rowland et al.; MRI study of hepatic tumours following high intensity focused ultrasound surgery; British Journal of Radiology; 70; pp. 144-153; Feb. 1997. |
| Roy et al.; A precise technique for the measurement of acoustic cavitation thresholds and some preliminary results; Journal of the Acoustical Society of America; vol. 78(5); pp. 1799-1805; Nov. 1985. |
| Sapareto et al.; Thermal dose determination in cancer therapy; Int J Radiat Oncol Biol Phys; 10(6); pp. 787-800; Apr. 1984. |
| Sapozhnikov et al.; Ultrasound-Guided Localized Detection of Cavitation During Lithotripsy in Pig Kidney in Vivo; IEEE Ultrasonics Symposium, vol. 2; pp. 1347-1350; Oct. 7-10, 2001. |
| Sato et al.; Experimental Investigation of Phased Array Using Tapered Matching Layers. 2002 IEEE Ultrasound Symposium. vol. 2; pp. 1235-1238, Oct. 2002. |
| Sferruzza et al.; Generation of high power unipolar pulse with a piezocomposite transducer; in 1999 IEEE Ultrasonics Symposium Proceedings; International Symposium (Cat. No. 99CH37027); vol. 2; pp. 1125-1128; Oct. 17, 1999. |
| Shung; Diagnostic Ultrasound: Imaging and Blood Flow Measurements; Taylor and Francis Group, LLC; Boca Raton, FL; 207 pages; (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue) 2006. |
| Simonin et al.; Characterization of heterogeneous structure in a polymer object manufactured by stereolithography with low-frequency microechography; Journal of Materials Chemistry; vol. 6, pp. 1595-1599, Sep. 1996. |
| Sokolov et al.; Use of a dual-pulse lithotripter to generate a localized and intensified cavitation field; Journal of the Acoustical Society of America; vol. 110(3); pp. 1685-1695; Sep. 2001. |
| Song et al.; Feasibility of Using Lateral Mode Coupling Method for a Large Scale Ultrasound Phased Array for Noninvasive Transcranial Therapy; Biomedical Engineering; IEEE Transactions on, vol. 57, pp. 124-133; Jan. 2010 (author manuscript). |
| Souchon et al.; Visualisation of HIFU lesions using elastography of the human prostate in vivo: Preliminary results; Ultrasound Med. Biol; 29(7); pp. 1007-1015; Jul. 2003. |
| Souquet et al.; Design of Low-Loss Wide-Band Ultrasonic Transducers for Noninvasive Medical Application; Sonics and Ultrasonics, IEEE Transactions on, vol. 26, pp. 75-80, Mar. 1979. |
| Therapeutic Ultrasound Group. Non-invasive Ultrasonic Tissue Fraction for Treatment of Benign Disease and Cancer—“Histotripsy”. University research [online]. Biomedical Engineering Department, University of Michigan. Jul. 2011 [retrieved on Jan. 28, 2014] from: (http://web.archive.org/web/20110720091822/http://www.histotripsy.umich.edu/index.html> entiredocument) Jul. 2011. |
| Toda; Narrowband impedance matching layer for high efficiency thickness mode ultrasonic transducers; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 49, pp. 299-306, Mar. 2002. |
| Urban et al.; Measurement of prostate viscoelasticity using shearwave dispersion ultrasound vibrometry (SDUV): an in vitro study; IEEE International Ultrasonics Symposium Proceedings (IUS); pp. 1141-1144; Oct. 11, 2010. |
| Van Kervel et al.; A calculation scheme for the optimum design of ultrasonic transducers; Ultrasonics, vol. 21, pp. 134-140, May 1983. |
| Wang et al.; Quantitative ultrasound backscatter for pulsed cavitational ultrasound therapy-histotripsy; Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 56, pp. 995-1005, May 2009. |
| Wikipedia; Medical ultrasound; 15 pages; retrieved from the internet (https://en.wikipedia.org/w/index.php?title=Medical_utrasound&oldid=515340960) on Jan. 12, 2018. |
| Wu et al.; Mechanism and dynamics of hydrodynamic-acoustic cavitation (HAC); Ultrasonics sonochemistry; vol. 49., pp. 89-96; Dec. 1, 2018. |
| Xie et al.; Correspondence of ultrasound elasticity imaging to direct mechanical measurement in aging DVT in rats; Ultrasound Med Biol; 31(10); pp. 1351-1359; Oct. 2005 (author manuscript, 20 pgs.). |
| Xu et al.; A new strategy to enhance cavitational tissue erosion by using a high intensity initiating sequence; IEEE Trans Ultrasonics Ferroelectrics and Freq Control; vol. 53(8); pp. 1412-1424; Aug. 2006. |
| Xu et al.; Controlled ultrasound tissue erosion: the role of dynamic interaction between insonation and microbubble activity; Journal of the Acoustical Society of America; vol. 117(1); pp. 424-435; Jan. 2005. |
| Xu et al.; Controlled ultrasound tissue erosion; IEEE Transaction on Ultrasonics, Ferroelectrics, and Frequency Control; vol. 51 (6); pp. 726-736; Jun. 2004. |
| Xu et al.; Effects of acoustic parameters on bubble cloud dynamics in ultrasound tissue erosion (histotripsy); Journal of the Acoustical Society of America; vol. 122(1); pp. 229-236; Jul. 2007. |
| Xu et al.; High Speed Imaging of Bubble Clouds Generated in Pulsed Ultrasound Cavitational Therapy Histotripsy; IEEE Trans Ultrason Ferroelectr Freq Control; ; vol. 54; No. 10; pp. 2091R2101; Oct. 2007. |
| Xu et al.; Investigation of intensity threshold for ultrasound tissue erosion; Ultrasound in Med. & Biol.; vol. 31(12); pp. 1673-1682; Dec. 2005. |
| Xu et al.; Optical and acoustic monitoring of bubble cloud dynamics at a tissue-fluid interface in ultrasound tissue erosion; Journal of the Acoustical Society of America; vol. 121(4); pp. 2421-2430; Apr. 2007. |
| Yan et al.; A review of rapid prototyping technologies and systems; Computer-Aided Design, vol. 28, pp. 307-318, Apr. 1996. |
| Zhang et al.; A fast tissue stiffness-dependent elastography for HIFU-induced lesions inspection; Ultrasonics; 51(8); pp. 857-869; Dec. 2011. |
| Zheng et al.; An acoustic backscatter-based method for localization of lesions induced by high-intensity focused ultrasound; Ultrasound Med Biol; 36(4); pp. 610-622; Apr. 2010. |
| Gateau et al.; Transcranial ultrasonic therapy based on time reversal of acoustically induced cavitation bubble signature. IEEE Transactions on Biomedical Engineering: 57(1); pp. 134-144; Sep. 18, 2009. |
| Cannata et al.; U.S. Appl. No. 18/311,050 entitled “Histotripsy systems and methods,” filed May 2, 2023. |
| Maxwell et al.; U.S. Appl. No. 18/329,459 entitled “Histotripsy for thrombolysis,” filed Jun. 5, 2023. |
| Xu et al.; U.S. Appl. No. 18/478,342 entitled “Systems and methods for histotripsy immunosensitization,” filed Sep. 29, 2023. |
| Duryea et al.; U.S. Appl. No. 18/497,856 entitled “Histotripsy systems and methods,” filed Oct. 31, 2023. |
| Duryea et al.; U.S. Appl. No. 18/498,979 entitled “Histotripsy systems and methods,” filed Oct. 31, 2023. |
| Bader et al.; For whom the bubble grows: physical principles of bubble nucleation and dynamics in histotripsy ultrasound therapy; Ultrasound in medicine & biology; 45(5); pp. 1056-1080, May 1, 2019. |
| Cain et al.; Concentric-ring and sector-vortex phased-array applicators for ultrasound hyperthermia; IEEE Transactions on Microwave Theory and Techniques; 34(5); pp. 542-551; May 1986. |
| Hynynen et al.; Feasibility of using ultrasound phased arrays for MRI monitored noninvasive surgery; IEEE transactions on ultrasonics, ferroelectrics, and frequency control; 43(6); pp. 1043-1053; Nov. 1996. |
| Xu et al.; U.S. Appl. No. 18/568,038 entitled “Minimally invasive histotripsy systems and methods,” filed Dec. 7, 2023. |
| Cannata et al.; U.S. Appl. No. 18/594,843 entitled “Histotripsy systems and methods,” filed Mar. 4, 2024. |
| Cannata et al.; U.S. Appl. No. 18/630,758 entitled “Histotripsy systems and methods,” filed Apr. 9, 2024. |
| Cannata et al.; U.S. Appl. No. 18/642,529 entitled “Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy,” filed Apr. 22, 2024. |
| Maxwell et al.; U.S. Appl. No. 18/737,731 entitled “Histotripsy for thrombolysis,” filed Jun. 7, 2024. |
| Cannata et al.; U.S. Appl. No. 18/737,746 entitled “Histotripsy excitation sequences optimized for bubble cloud formation using shoock scattering,” filed Jun. 7, 2024. |
| Stopek.; U.S. Appl. No. 18/761,937 entitled “Minimally invasive histotripsy systems and methods,” filed Jul. 2, 2024. |
| International Society for Magnetic Resonance in Medicine (ISMRM); No. 105; XP040714022;I Jul. 24, 2020. |
| Hoogenboom et al.; Mechanical high-intensity focused ultrasound destruction of soft tissue: working mechanisms and physiologic effects; Ultrasound in medicine & biology; 41(6); pp. 1500-1517; Jun. 1, 2015. |
| Sukovich et al.; Real-time transcranial histotripsy treatment localization and mapping using acoustic cavitation emission feedback; IEEE transactions on ultrasonics, ferroelectrics, and frequency control; 67(6); pp. 1178-1791; Jan. 17, 2020. |
| Number | Date | Country | |
|---|---|---|---|
| 20240139552 A1 | May 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63381401 | Oct 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 18497856 | Oct 2023 | US |
| Child | 18498966 | US |
